{
  "drug_name": "baricitinib",
  "generic_name": "baricitinib",
  "mechanism": "Janus Kinase Inhibitor",
  "target": null,
  "approved_indications": [
    "adults with severe alopecia areata",
    "covid-19 in certain hospitalized adults",
    "adults with moderately-to-severely active rheumatoid arthritis",
    "moderately-to-severely active rheumatoid arthritis"
  ],
  "opportunities": [
    {
      "extraction": {
        "source": {
          "pmid": "39541169",
          "doi": "10.1172/JCI179436",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39541169/",
          "title": "Rapid response of lichen planus to baricitinib associated with suppression of cytotoxic CXCL13+CD8+ T cells.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Cutaneous lichen planus",
        "disease_normalized": "Lichen Planus",
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 12,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "topical steroids",
            "oral steroids",
            "intramuscular steroids",
            "methotrexate",
            "topical calcineurin inhibitors"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "12 patients with cutaneous LP, mean age 63.6 years, 91.7% female, 75% White, mean disease duration 26.5 months, all had refractory disease"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "2 mg daily for 16 weeks, with optional dose escalation to 4 mg daily for additional 12 weeks",
          "frequency": null,
          "duration": "16 weeks primary treatment period, with optional 12-week dose escalation",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "10/12 (83.3%)",
          "responders_n": 10,
          "responders_pct": 83.3,
          "time_to_response": "As early as week 1 in 37.5% of patients, 100% of patients by week 12",
          "duration_of_response": "Treatment effects were sustained at week 20 (4 weeks off therapy)",
          "effect_size_description": "Large effect size with 83.3% response rate, 5 patients completely clear (PGA=0), 5 almost clear (PGA=1)",
          "primary_endpoint": "Treatment response defined as physician global assessment (PGA) scores of 0-3 with \u226550% score reduction at week 16",
          "endpoint_result": "10 of 12 patients (83.3%) achieved treatment response at week 16",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib demonstrated high efficacy in cutaneous lichen planus with 83.3% of patients achieving treatment response. Significant improvements were seen in lesion count, body surface area affected, pruritus, pain, and quality of life measures. Response was sustained 4 weeks after treatment discontinuation."
        },
        "safety": {
          "adverse_events": [
            "absolute neutrophil count decrease"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Treatment was well tolerated with 12 total adverse events, mostly mild or moderate. Only one mild AE was deemed probably related to study drug (neutropenia). No adverse events led to discontinuation of baricitinib.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "20 weeks (4 weeks post-treatment)",
        "key_findings": "Baricitinib showed rapid and sustained response in refractory cutaneous lichen planus with molecular evidence of suppression of cytotoxic CXCL13+CD8+ T cells and IFN signaling.",
        "extraction_timestamp": "2025-12-05T19:19:11.760447",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "Lichen Planus",
        "epidemiology": {
          "us_prevalence_estimate": "0.15-0.42% of US adults",
          "us_incidence_estimate": "11.4 per 100,000 person-years (oral lichen planus)",
          "global_prevalence": null,
          "patient_population_size": 956250,
          "prevalence_source": "Journal of the American Academy of Dermatology and Explorys database",
          "prevalence_source_url": "https://www.jaad.org/article/S0190-9622(21)02974-1/fulltext",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Topical corticosteroids",
              "drug_class": "Corticosteroids",
              "efficacy_range": "70-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 1500.0,
              "line_of_therapy": null,
              "notes": "Off-label, most commonly prescribed (97.8% of dermatologists)"
            },
            {
              "drug_name": "Topical calcineurin inhibitors",
              "drug_class": "Immunomodulators",
              "efficacy_range": "60-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 8000.0,
              "line_of_therapy": null,
              "notes": "Off-label, used by 67.7% of dermatologists"
            },
            {
              "drug_name": "Intralesional corticosteroids",
              "drug_class": "Corticosteroids",
              "efficacy_range": "65-75%",
              "efficacy_pct": null,
              "annual_cost_usd": 3000.0,
              "line_of_therapy": null,
              "notes": "Off-label, used by 64.8% of dermatologists"
            },
            {
              "drug_name": "Oral immunosuppressants",
              "drug_class": "Immunosuppressants",
              "efficacy_range": "50-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 15000.0,
              "line_of_therapy": null,
              "notes": "Off-label, used by 50.6% of dermatologists"
            },
            {
              "drug_name": "Narrowband UVB",
              "drug_class": "Phototherapy",
              "efficacy_range": "50-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 5000.0,
              "line_of_therapy": null,
              "notes": "Off-label, used by 40.7% of dermatologists"
            },
            {
              "drug_name": "Topical vitamin D analogues",
              "drug_class": "Vitamin D analogues",
              "efficacy_range": "40-50%",
              "efficacy_pct": null,
              "annual_cost_usd": 4000.0,
              "line_of_therapy": null,
              "notes": "Off-label, used by 33.3% of dermatologists"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 1,
          "pipeline_details": "Ruxolitinib cream shows promise in treating lichen planus and is being investigated",
          "avg_annual_cost_usd": 6000.0,
          "treatment_paradigm": "Stepwise approach starting with topical corticosteroids as first-line, followed by topical calcineurin inhibitors, intralesional steroids, then systemic immunosuppressants and phototherapy for refractory cases",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved treatments exist for lichen planus, despite 25.6% of dermatologists mistakenly believing approved treatments are available. Significant variability in management practices without standardized guidelines.",
          "competitive_landscape": "Lichen planus has no FDA-approved therapies, with treatment relying entirely on off-label use of topical and systemic immunosuppressive agents. The lack of approved treatments and standardized guidelines represents a significant unmet need for this relatively common dermatologic condition affecting predominantly women over 60.",
          "soc_source": "Medscape - Survey Identifies Gaps in Lichen Planus Management, https://www.medscape.com/viewarticle/survey-identifies-gaps-lichen-planus-management-2025a1000a90"
        },
        "market_size_estimate": "$5.7B",
        "market_size_usd": 5737500000.0,
        "growth_rate": "5-8% CAGR (high unmet need)"
      },
      "scores": {
        "clinical_signal": 10.0,
        "evidence_quality": 6.3,
        "market_opportunity": 9.7,
        "overall_priority": 9.0,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 10.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 6.0,
          "publication_venue": 10.0,
          "followup_duration": 3.0
        },
        "sample_size_score": 6.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 3.0,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 9.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 9.0,
        "unmet_need_score": 10.0
      },
      "rank": 1
    },
    {
      "extraction": {
        "source": {
          "pmid": "35096866",
          "doi": "10.3389/fmed.2021.764067",
          "url": "https://www.semanticscholar.org/paper/8eb489dd88a10d89629139d8d8798aae6258d47c",
          "title": "Effectiveness of Baricitinib in Refractory Seronegative Rheumatoid Arthritis and Uveitis: A Case Report",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Uveitis (bilateral non-granulomatous panuveitis)",
        "disease_normalized": "Uveitis",
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "steroids",
            "methotrexate",
            "salazosulfapyridine",
            "adalimumab",
            "infliximab"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "35-year-old man with seronegative rheumatoid arthritis complicated by bilateral severe non-granulomatous panuveitis"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "8 mg/day",
          "frequency": null,
          "duration": "2 years and 7 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "3 months",
          "duration_of_response": "2 years and 7 months with no relapse observed",
          "effect_size_description": "Complete resolution of vitreous opacity, serous retinal detachment, anterior chamber cells, and corneal infiltrative lesions",
          "primary_endpoint": "Improvement in uveitis inflammatory activity",
          "endpoint_result": "Complete improvement in vitreous opacity, serous retinal detachment, and anterior chamber cells",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib achieved complete resolution of refractory uveitis symptoms including vitreous opacity, serous retinal detachment, and anterior chamber cells within 3 months. The response was sustained for 2 years and 7 months without relapse, while maintaining good visual acuity of 20/20 in both eyes."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No serious side effects of oral baricitinib were observed or reported during the 2 years and 7 months treatment period. The patient tolerated the medication well with no adverse events requiring discontinuation.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "2 years and 7 months",
        "key_findings": "Baricitinib was effective for refractory uveitis associated with seronegative rheumatoid arthritis when conventional DMARDs and TNF-\u03b1 inhibitors failed, providing a new treatment option for refractory uveitis.",
        "extraction_timestamp": "2025-12-05T19:24:14.896165",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "Uveitis",
        "epidemiology": {
          "us_prevalence_estimate": "234 per 100,000 persons",
          "us_incidence_estimate": "52 cases per 100,000 persons annually",
          "global_prevalence": null,
          "patient_population_size": 784000,
          "prevalence_source": "IOVS - ARVO Journals",
          "prevalence_source_url": "https://iovs.arvojournals.org/article.aspx?articleid=2807096",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Humira (adalimumab)",
              "drug_class": "TNF inhibitor",
              "efficacy_range": "60-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 80000.0,
              "line_of_therapy": null,
              "notes": "FDA approved for non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years and older"
            },
            {
              "drug_name": "Corticosteroid eye drops",
              "drug_class": "Corticosteroid",
              "efficacy_range": "50-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 2000.0,
              "line_of_therapy": null,
              "notes": "First FDA-approved treatment for non-infectious uveitis"
            },
            {
              "drug_name": "Cyclopentolate (Cyclogyl)",
              "drug_class": "Anticholinergic agent",
              "efficacy_range": "N/A",
              "efficacy_pct": null,
              "annual_cost_usd": 500.0,
              "line_of_therapy": null,
              "notes": "FDA approved for symptomatic relief - blocks nerve impulses to ease pain and photophobia"
            },
            {
              "drug_name": "Infliximab",
              "drug_class": "TNF inhibitor",
              "efficacy_range": "60-75%",
              "efficacy_pct": null,
              "annual_cost_usd": 75000.0,
              "line_of_therapy": null,
              "notes": "Off-label use - chimeric monoclonal antibody targeting TNF-alpha"
            },
            {
              "drug_name": "Amjevita (adalimumab-atto)",
              "drug_class": "TNF inhibitor biosimilar",
              "efficacy_range": "60-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 65000.0,
              "line_of_therapy": null,
              "notes": "FDA approved biosimilar to Humira for uveitis indication"
            }
          ],
          "approved_drug_names": [
            "Humira (adalimumab)",
            "Corticosteroid eye drops",
            "Cyclopentolate (Cyclogyl)",
            "Amjevita (adalimumab-atto)"
          ],
          "num_approved_drugs": 4,
          "num_pipeline_therapies": 0,
          "pipeline_details": null,
          "avg_annual_cost_usd": 44500.0,
          "treatment_paradigm": "Treatment typically starts with topical corticosteroids for local inflammation control, with adalimumab (TNF inhibitor) as FDA-approved systemic therapy for non-infectious intermediate, posterior, and panuveitis when topical treatment is insufficient",
          "unmet_need": true,
          "unmet_need_description": "Limited FDA-approved systemic options with only adalimumab specifically approved for uveitis, significant risk of vision loss if inadequately treated, and need for long-term immunosuppression with associated risks",
          "competitive_landscape": "The uveitis treatment market is dominated by Humira (adalimumab) as the only FDA-approved systemic biologic, with corticosteroids as first-line topical therapy. Significant unmet need exists for additional targeted therapies given the limited approved options and chronic nature requiring long-term treatment.",
          "soc_source": "Medscape Iritis and Uveitis Medication - https://emedicine.medscape.com/article/798323-medication"
        },
        "market_size_estimate": "$34.9B",
        "market_size_usd": 34888000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)"
      },
      "scores": {
        "clinical_signal": 10.0,
        "evidence_quality": 4.3,
        "market_opportunity": 8.3,
        "overall_priority": 8.2,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 10.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "followup_duration": 10.0
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 10.0,
        "market_breakdown": {
          "competitors": 5.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 5.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 2
    },
    {
      "extraction": {
        "source": {
          "pmid": "40115257",
          "doi": "10.3389/fphar.2025.1509404",
          "url": "https://www.semanticscholar.org/paper/f652d9aee27e16ab02f39c9e99a4ee0e3777430d",
          "title": "Case report: Effectiveness of Janus kinase inhibitors in the management of isolated noninfectious uveitis: a case series",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "isolated noninfectious uveitis",
        "disease_normalized": "Uveitis",
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 3,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "methylprednisolone",
            "mycophenolate mofetil",
            "adalimumab",
            "tacrolimus",
            "methotrexate",
            "cyclosporine"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "3 patients (1 female, 2 male) aged 28-59 years with isolated noninfectious uveitis (anterior, intermediate, and posterior types)"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg daily",
          "frequency": null,
          "duration": "mean follow-up 31.6 months (range 16-55 months)",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "3/3 (100%)",
          "responders_n": 3,
          "responders_pct": 100.0,
          "time_to_response": "mean 6.3 months (range 4-9 months)",
          "duration_of_response": ">1 year in all patients",
          "effect_size_description": "complete remission in all patients with sustained response",
          "primary_endpoint": "remission of uveitis",
          "endpoint_result": "all 3 patients achieved remission lasting >1 year",
          "durability_signal": null,
          "efficacy_summary": "All three patients with refractory isolated noninfectious uveitis achieved complete remission after JAK inhibitor therapy. Mean visual acuity improved from 0.4 to 0.6 (Snellen), with sustained remission lasting over 1 year in all cases."
        },
        "safety": {
          "adverse_events": [
            "transient elevation in liver transaminases"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No significant side effects were observed in any patients throughout the follow-up period. Only one patient experienced a slight temporary increase in liver transaminase levels.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "mean 31.6 months (range 16-55 months)",
        "key_findings": "This is the first report documenting successful use of baricitinib and upadacitinib in isolated noninfectious uveitis, with all patients achieving sustained remission after failing conventional treatments.",
        "extraction_timestamp": "2025-12-05T19:21:41.946049",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "Uveitis",
        "epidemiology": {
          "us_prevalence_estimate": "234 per 100,000 persons",
          "us_incidence_estimate": "52 cases per 100,000 persons annually",
          "global_prevalence": null,
          "patient_population_size": 784000,
          "prevalence_source": "IOVS - ARVO Journals",
          "prevalence_source_url": "https://iovs.arvojournals.org/article.aspx?articleid=2807096",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Humira (adalimumab)",
              "drug_class": "TNF inhibitor",
              "efficacy_range": "60-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 80000.0,
              "line_of_therapy": null,
              "notes": "FDA approved for non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years and older"
            },
            {
              "drug_name": "Corticosteroid eye drops",
              "drug_class": "Corticosteroid",
              "efficacy_range": "50-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 2000.0,
              "line_of_therapy": null,
              "notes": "First FDA-approved treatment for non-infectious uveitis"
            },
            {
              "drug_name": "Cyclopentolate (Cyclogyl)",
              "drug_class": "Anticholinergic agent",
              "efficacy_range": "N/A",
              "efficacy_pct": null,
              "annual_cost_usd": 500.0,
              "line_of_therapy": null,
              "notes": "FDA approved for symptomatic relief - blocks nerve impulses to ease pain and photophobia"
            },
            {
              "drug_name": "Infliximab",
              "drug_class": "TNF inhibitor",
              "efficacy_range": "60-75%",
              "efficacy_pct": null,
              "annual_cost_usd": 75000.0,
              "line_of_therapy": null,
              "notes": "Off-label use - chimeric monoclonal antibody targeting TNF-alpha"
            },
            {
              "drug_name": "Amjevita (adalimumab-atto)",
              "drug_class": "TNF inhibitor biosimilar",
              "efficacy_range": "60-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 65000.0,
              "line_of_therapy": null,
              "notes": "FDA approved biosimilar to Humira for uveitis indication"
            }
          ],
          "approved_drug_names": [
            "Humira (adalimumab)",
            "Corticosteroid eye drops",
            "Cyclopentolate (Cyclogyl)",
            "Amjevita (adalimumab-atto)"
          ],
          "num_approved_drugs": 4,
          "num_pipeline_therapies": 0,
          "pipeline_details": null,
          "avg_annual_cost_usd": 44500.0,
          "treatment_paradigm": "Treatment typically starts with topical corticosteroids for local inflammation control, with adalimumab (TNF inhibitor) as FDA-approved systemic therapy for non-infectious intermediate, posterior, and panuveitis when topical treatment is insufficient",
          "unmet_need": true,
          "unmet_need_description": "Limited FDA-approved systemic options with only adalimumab specifically approved for uveitis, significant risk of vision loss if inadequately treated, and need for long-term immunosuppression with associated risks",
          "competitive_landscape": "The uveitis treatment market is dominated by Humira (adalimumab) as the only FDA-approved systemic biologic, with corticosteroids as first-line topical therapy. Significant unmet need exists for additional targeted therapies given the limited approved options and chronic nature requiring long-term treatment.",
          "soc_source": "Medscape Iritis and Uveitis Medication - https://emedicine.medscape.com/article/798323-medication"
        },
        "market_size_estimate": "$34.9B",
        "market_size_usd": 34888000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)"
      },
      "scores": {
        "clinical_signal": 10.0,
        "evidence_quality": 3.7,
        "market_opportunity": 8.3,
        "overall_priority": 8.0,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 10.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 2.0,
          "publication_venue": 2.0,
          "followup_duration": 7.0
        },
        "sample_size_score": 2.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 7.0,
        "market_breakdown": {
          "competitors": 5.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 5.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 3
    },
    {
      "extraction": {
        "source": {
          "pmid": "38463557",
          "doi": "10.2147/CCID.S446468",
          "url": "https://www.semanticscholar.org/paper/3042dd9238d395b004db932402833376fb860849",
          "title": "Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome with Baricitinib, a Janus Kinase Inhibitor",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "SAPHO syndrome (Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis)",
        "disease_normalized": "SAPHO Syndrome",
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "NSAIDs",
            "corticosteroids",
            "DMARDs",
            "adalimumab",
            "acitretin capsules"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "32-year-old Chinese woman with refractory SAPHO syndrome presenting with recurrent osteoarticular pain for over one year and skin erythema pustulosis for 11 months"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "2 mg twice daily initially, then halved",
          "frequency": null,
          "duration": "Initial treatment with improvement at 2 weeks, then dose halved and continued for 3 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "2 weeks",
          "duration_of_response": "Sustained response for 3 months follow-up with no recurrence",
          "effect_size_description": "VAS pain score decreased from 9 to 2, complete skin lesion resolution",
          "primary_endpoint": "Improvement in skin lesions and osteoarticular pain",
          "endpoint_result": "Complete resolution of skin lesions and significant relief of osteoarticular pain within 2 weeks",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib achieved rapid and complete resolution of both skin lesions and osteoarticular pain within 2 weeks in a patient with refractory SAPHO syndrome. Laboratory markers normalized and pain scores dramatically improved from 9 to 2 on VAS scale."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse effects were observed during treatment or follow-up period. The patient tolerated dose reduction well with continued efficacy.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "3 months",
        "key_findings": "Baricitinib successfully treated refractory SAPHO syndrome with rapid onset of action and sustained response, suggesting JAK inhibition as a promising therapeutic approach for this rare autoimmune condition.",
        "extraction_timestamp": "2025-12-05T19:22:51.799837",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "SAPHO Syndrome",
        "epidemiology": {
          "us_prevalence_estimate": "1 in 10,000",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 33500,
          "prevalence_source": "BMJ RMD Open",
          "prevalence_source_url": "https://rmdopen.bmj.com/content/9/4/e003688",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Humira (adalimumab)",
              "drug_class": "TNF-alpha inhibitor",
              "efficacy_range": "60-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 80000.0,
              "line_of_therapy": null,
              "notes": "Off-label use, case reports show effectiveness for SAPHO syndrome"
            },
            {
              "drug_name": "Remicade (infliximab)",
              "drug_class": "TNF-alpha inhibitor",
              "efficacy_range": "60-75%",
              "efficacy_pct": null,
              "annual_cost_usd": 75000.0,
              "line_of_therapy": null,
              "notes": "Off-label use, case reports for acne fulminans with SAPHO"
            },
            {
              "drug_name": "Enbrel (etanercept)",
              "drug_class": "TNF-alpha inhibitor",
              "efficacy_range": "50-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 70000.0,
              "line_of_therapy": null,
              "notes": "Off-label use, case reports for sacroiliitis in SAPHO"
            },
            {
              "drug_name": "Kineret (anakinra)",
              "drug_class": "IL-1 receptor antagonist",
              "efficacy_range": "50-65%",
              "efficacy_pct": null,
              "annual_cost_usd": 55000.0,
              "line_of_therapy": null,
              "notes": "Off-label use, mentioned for acne fulminans treatment"
            },
            {
              "drug_name": "Corticosteroids",
              "drug_class": "Corticosteroid",
              "efficacy_range": "40-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 2000.0,
              "line_of_therapy": null,
              "notes": "Standard treatment, especially combined with debridement"
            },
            {
              "drug_name": "NSAIDs",
              "drug_class": "Anti-inflammatory",
              "efficacy_range": "30-50%",
              "efficacy_pct": null,
              "annual_cost_usd": 1500.0,
              "line_of_therapy": null,
              "notes": "Symptomatic relief for joint inflammation"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 0,
          "pipeline_details": null,
          "avg_annual_cost_usd": 47250.0,
          "treatment_paradigm": "No FDA-approved therapies exist. Treatment is primarily off-label with TNF-alpha inhibitors showing promise in case reports, combined with corticosteroids and supportive care for bone and joint manifestations",
          "unmet_need": true,
          "unmet_need_description": "SAPHO syndrome has no FDA-approved treatments and relies entirely on off-label therapies. Treatment responses are variable and many patients experience chronic symptoms affecting bones, joints, and skin with limited therapeutic options",
          "competitive_landscape": "SAPHO syndrome represents a significant unmet medical need with no approved therapies, relying on off-label use of biologics like adalimumab and infliximab. The rare nature of the disease limits clinical trial development, leaving patients dependent on case report evidence and physician experience.",
          "soc_source": "Medscape Medical Reference - https://emedicine.medscape.com/article/1072815-treatment"
        },
        "market_size_estimate": "$1.6B",
        "market_size_usd": 1582875000.0,
        "growth_rate": "5-8% CAGR (high unmet need)"
      },
      "scores": {
        "clinical_signal": 10.0,
        "evidence_quality": 2.7,
        "market_opportunity": 9.3,
        "overall_priority": 8.0,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 10.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "followup_duration": 5.0
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 5.0,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 4
    },
    {
      "extraction": {
        "source": {
          "pmid": "39415009",
          "doi": "10.1038/s41586-024-08061-0",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39415009/",
          "title": "Spatial proteomics identifies JAKi as treatment for a lethal skin disease.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Toxic epidermal necrolysis (TEN)",
        "disease_normalized": "Toxic Epidermal Necrolysis",
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 7,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "patients with toxic epidermal necrolysis"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "not specified",
          "frequency": null,
          "duration": "not specified",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "7/7 (100%)",
          "responders_n": 7,
          "responders_pct": 100.0,
          "time_to_response": "rapid",
          "duration_of_response": null,
          "effect_size_description": "rapid cutaneous re-epithelialization and recovery",
          "primary_endpoint": "cutaneous re-epithelialization and recovery",
          "endpoint_result": "rapid cutaneous re-epithelialization and recovery in all 7 patients",
          "durability_signal": null,
          "efficacy_summary": "Treatment with JAK inhibitors including baricitinib was associated with rapid cutaneous re-epithelialization and recovery in all seven patients with TEN. This represents a potential breakthrough treatment for a previously fatal condition with no effective therapy."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Treatment with JAK inhibitors was described as safe in all seven patients with TEN. No specific adverse events were reported in this case series.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "JAK inhibitors including baricitinib demonstrated potential as a curative therapy for TEN, a previously fatal skin condition with no effective treatment options.",
        "extraction_timestamp": "2025-12-05T19:18:20.019198",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "Toxic Epidermal Necrolysis",
        "epidemiology": {
          "us_prevalence_estimate": null,
          "us_incidence_estimate": "1.9 per million adults per year",
          "global_prevalence": null,
          "patient_population_size": 637,
          "prevalence_source": "StatPearls - NCBI Bookshelf",
          "prevalence_source_url": "https://www.ncbi.nlm.nih.gov/books/NBK574530/",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Intravenous Immunoglobulin (IVIG)",
              "drug_class": "Immunoglobulin",
              "efficacy_range": "40-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 25000.0,
              "line_of_therapy": null,
              "notes": "Off-label, most commonly used treatment"
            },
            {
              "drug_name": "Cyclosporine",
              "drug_class": "Calcineurin inhibitor",
              "efficacy_range": "50-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 8000.0,
              "line_of_therapy": null,
              "notes": "Off-label, case reports show efficacy"
            },
            {
              "drug_name": "Corticosteroids",
              "drug_class": "Corticosteroid",
              "efficacy_range": "30-50%",
              "efficacy_pct": null,
              "annual_cost_usd": 2000.0,
              "line_of_therapy": null,
              "notes": "Off-label, controversial due to infection risk"
            },
            {
              "drug_name": "Supportive care",
              "drug_class": "Supportive therapy",
              "efficacy_range": "20-40%",
              "efficacy_pct": null,
              "annual_cost_usd": 15000.0,
              "line_of_therapy": null,
              "notes": "Standard of care - wound care, fluid management"
            }
          ],
          "approved_drug_names": [
            "Supportive care"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 0,
          "pipeline_details": null,
          "avg_annual_cost_usd": 12500.0,
          "treatment_paradigm": "Immediate discontinuation of causative drug, supportive care with wound management and fluid/electrolyte balance, followed by immunomodulatory therapy such as IVIG or cyclosporine",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved specific treatments exist, high mortality rate (30-50%), reliance on off-label immunomodulatory therapies with limited evidence base",
          "competitive_landscape": "Currently no FDA-approved specific treatments for TEN exist, with management relying on supportive care and off-label use of immunomodulatory agents. Significant unmet need exists for approved therapies given the high mortality and limited treatment options.",
          "soc_source": "FDA Drug Safety Communications and Stevens-Johnson Syndrome Treatment Guidelines from https://www.fda.gov/drugs/drug-safety-and-availability/"
        },
        "market_size_estimate": "$8M",
        "market_size_usd": 7962500.0,
        "growth_rate": "5-8% CAGR (high unmet need)"
      },
      "scores": {
        "clinical_signal": 9.5,
        "evidence_quality": 6.3,
        "market_opportunity": 6.3,
        "overall_priority": 7.9,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 9.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 9.0,
        "evidence_breakdown": {
          "sample_size": 4.0,
          "publication_venue": 10.0,
          "followup_duration": 5.0
        },
        "sample_size_score": 4.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 5.0,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 2.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 2.0,
        "unmet_need_score": 10.0
      },
      "rank": 5
    },
    {
      "extraction": {
        "source": {
          "pmid": "35510170",
          "doi": "10.1177/1759720X221093211",
          "url": "https://www.semanticscholar.org/paper/c93d597cfaaf21fd7c0497c8b384d8f0ffc6d476",
          "title": "Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Blau syndrome",
        "disease_normalized": "Blau Syndrome",
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "acetylsalicylic acid",
            "methotrexate",
            "methylprednisolone",
            "etanercept",
            "anakinra",
            "abatacept",
            "adalimumab",
            "tofacitinib"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "25-year-old woman with severe refractory Blau syndrome with granulomatous dermatitis, arthritis, and uveitis"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg daily",
          "frequency": null,
          "duration": "4 months reported",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "maintained stable control since initiation",
          "duration_of_response": "ongoing at 4 months",
          "effect_size_description": "maintained adequate control of disease activity",
          "primary_endpoint": "clinical control of cutaneous, ocular, and joint manifestations",
          "endpoint_result": "cutaneous, ocular, and joint manifestations remained stable",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib successfully maintained disease control after tofacitinib discontinuation. Patient remained stable with controlled cutaneous, ocular, and joint manifestations throughout the 4-month follow-up period."
        },
        "safety": {
          "adverse_events": [
            "lymphopenia"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Baricitinib showed an adequate safety profile with mild lymphopenia observed at 4 months (800 cells/\u00b5l) but no discontinuation required. No serious adverse events reported during the treatment period.",
          "safety_profile": "Acceptable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "4 months",
        "key_findings": "First reported successful use of baricitinib in Blau syndrome, maintaining disease control with acceptable safety profile after tofacitinib discontinuation due to severe lymphopenia.",
        "extraction_timestamp": "2025-12-05T19:24:59.281967",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "Blau Syndrome",
        "epidemiology": {
          "us_prevalence_estimate": "fewer than 1000 patients",
          "us_incidence_estimate": "1/1,670,000 per year for children <5 years",
          "global_prevalence": null,
          "patient_population_size": 1000,
          "prevalence_source": "Orphanet and Dermatology Times",
          "prevalence_source_url": "https://www.orpha.net/en/disease/detail/90340",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Humira (adalimumab)",
              "drug_class": "TNF inhibitor",
              "efficacy_range": "50-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 80000.0,
              "line_of_therapy": null,
              "notes": "Off-label use for uveitis component, FDA approved for uveitis"
            },
            {
              "drug_name": "Kineret (anakinra)",
              "drug_class": "IL-1 receptor antagonist",
              "efficacy_range": "40-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 60000.0,
              "line_of_therapy": null,
              "notes": "Off-label use for autoinflammatory features"
            },
            {
              "drug_name": "Oral macrolides",
              "drug_class": "Antibiotic",
              "efficacy_range": "30-50%",
              "efficacy_pct": null,
              "annual_cost_usd": 2000.0,
              "line_of_therapy": null,
              "notes": "Off-label for dermatologic manifestations"
            },
            {
              "drug_name": "Methotrexate",
              "drug_class": "DMARD",
              "efficacy_range": "40-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 5000.0,
              "line_of_therapy": null,
              "notes": "Off-label immunosuppressive therapy"
            },
            {
              "drug_name": "Corticosteroids",
              "drug_class": "Steroid",
              "efficacy_range": "50-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 3000.0,
              "line_of_therapy": null,
              "notes": "Off-label anti-inflammatory therapy"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 0,
          "pipeline_details": null,
          "avg_annual_cost_usd": 30000.0,
          "treatment_paradigm": "Symptomatic management with immunosuppressive agents targeting inflammation in skin, joints, and eyes. Treatment is primarily off-label using drugs effective for related autoinflammatory conditions.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved therapies specifically for Blau syndrome. Current treatments are off-label and provide only symptomatic relief without addressing underlying NOD2 dysfunction. Limited treatment options for this rare genetic autoinflammatory disorder.",
          "competitive_landscape": "Blau syndrome has no FDA-approved treatments, with management relying on off-label use of biologics and immunosuppressants used for related autoinflammatory conditions. Significant unmet need exists for targeted therapies addressing the underlying NOD2 genetic defect in this rare pediatric disorder.",
          "soc_source": "FDA curriculum vitae documents mentioning Blau syndrome research and treatment approaches"
        },
        "market_size_estimate": "$30M",
        "market_size_usd": 30000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)"
      },
      "scores": {
        "clinical_signal": 10.0,
        "evidence_quality": 2.7,
        "market_opportunity": 8.0,
        "overall_priority": 7.7,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 10.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "followup_duration": 5.0
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 5.0,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 4.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 4.0,
        "unmet_need_score": 10.0
      },
      "rank": 6
    },
    {
      "extraction": {
        "source": {
          "pmid": "39841460",
          "doi": "10.1001/jamadermatol.2024.5737",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39841460/",
          "title": "Combination of Baricitinib and Phototherapy in Adults With Active Vitiligo: A Randomized Clinical Trial.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "vitiligo",
        "disease_normalized": "Vitiligo",
        "is_off_label": true,
        "evidence_level": "Retrospective Study",
        "patient_population": {
          "n_patients": 49,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "adults with active and extensive vitiligo disease, the most severe form of vitiligo"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": null,
          "frequency": null,
          "duration": "36 weeks",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "35.6 percentage point greater improvement in VASI score compared to placebo",
          "primary_endpoint": "change in total Vitiligo Area Scoring Index (VASI) score",
          "endpoint_result": "-44.8% change in VASI score for baricitinib group vs -9.2% for placebo group",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib combined with narrowband UV-B phototherapy demonstrated significant efficacy in treating severe active vitiligo. The treatment resulted in rapid and clinically meaningful repigmentation with a 44.8% reduction in VASI score compared to 9.2% with placebo."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "The abstract mentions tolerance of the combination therapy but specific safety data are not provided in the available text.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "36 weeks",
        "key_findings": "Baricitinib combined with phototherapy provided clinically meaningful repigmentation in severe active vitiligo with 44.8% reduction in disease severity.",
        "extraction_timestamp": "2025-12-05T19:18:38.573158",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "Vitiligo",
        "epidemiology": {
          "us_prevalence_estimate": "0.76% to 1.11%",
          "us_incidence_estimate": "22.6 per 100,000 person-years",
          "global_prevalence": null,
          "patient_population_size": 2350000,
          "prevalence_source": "PMC - NIH",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8600454/",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Opzelura (ruxolitinib)",
              "drug_class": "JAK inhibitor",
              "efficacy_range": "40-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 65000.0,
              "line_of_therapy": null,
              "notes": "FDA-approved for nonsegmental vitiligo in patients 12+ years"
            },
            {
              "drug_name": "Topical corticosteroids",
              "drug_class": "Corticosteroid",
              "efficacy_range": "30-50%",
              "efficacy_pct": null,
              "annual_cost_usd": 2000.0,
              "line_of_therapy": null,
              "notes": "Off-label, standard first-line therapy"
            },
            {
              "drug_name": "PUVA therapy (psoralen + UVA)",
              "drug_class": "Phototherapy",
              "efficacy_range": "45-75%",
              "efficacy_pct": null,
              "annual_cost_usd": 8000.0,
              "line_of_therapy": null,
              "notes": "Off-label photochemotherapy"
            },
            {
              "drug_name": "Narrow-band UVB",
              "drug_class": "Phototherapy",
              "efficacy_range": "40-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 6000.0,
              "line_of_therapy": null,
              "notes": "Off-label light therapy"
            },
            {
              "drug_name": "Topical calcineurin inhibitors",
              "drug_class": "Immunosuppressant",
              "efficacy_range": "30-45%",
              "efficacy_pct": null,
              "annual_cost_usd": 3000.0,
              "line_of_therapy": null,
              "notes": "Off-label, tacrolimus/pimecrolimus"
            }
          ],
          "approved_drug_names": [
            "Opzelura (ruxolitinib)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 3,
          "pipeline_details": "JAK inhibitors in development, prostaglandin analogs, and melanocyte transplantation techniques in various clinical trial phases",
          "avg_annual_cost_usd": 16800.0,
          "treatment_paradigm": "Topical therapies as first-line (corticosteroids, Opzelura), followed by phototherapy (NB-UVB, PUVA), with surgical options for stable, localized disease",
          "unmet_need": true,
          "unmet_need_description": "Limited treatment options with modest efficacy, slow response rates requiring months of treatment, and complete repigmentation achieved in minority of patients",
          "competitive_landscape": "Opzelura is the only FDA-approved pharmacologic treatment for vitiligo, representing a significant advance but with limited efficacy. Substantial unmet need remains given modest response rates and lack of curative treatments for this psychologically impactful condition.",
          "soc_source": "FDA Drug Approval Database and NIAMS - https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older"
        },
        "market_size_estimate": "$39.5B",
        "market_size_usd": 39480000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)"
      },
      "scores": {
        "clinical_signal": 7.0,
        "evidence_quality": 7.0,
        "market_opportunity": 9.0,
        "overall_priority": 7.5,
        "clinical_breakdown": {
          "response_rate": 9.0,
          "safety_profile": 5.0
        },
        "response_rate_score": 9.0,
        "safety_profile_score": 5.0,
        "evidence_breakdown": {
          "sample_size": 8.0,
          "publication_venue": 10.0,
          "followup_duration": 3.0
        },
        "sample_size_score": 8.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 3.0,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 7
    },
    {
      "extraction": {
        "source": {
          "pmid": "36419482",
          "doi": "10.1177/1759720X221137126",
          "url": "https://www.semanticscholar.org/paper/869f10eec990650fa66b182fc661f1113c3dd59b",
          "title": "Baricitinib in severe and refractory peripheral ulcerative keratitis: a case report and literature review",
          "authors": "Calvo-R\u00edo et al.",
          "journal": null,
          "year": 2021,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Peripheral ulcerative keratitis (PUK)",
        "disease_normalized": "Peripheral Ulcerative Keratitis",
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "methotrexate",
            "leflunomide",
            "certolizumab pegol",
            "adalimumab",
            "tocilizumab",
            "intravenous methylprednisolone"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "85-year-old woman with rheumatoid arthritis and secondary Sj\u00f6gren's syndrome with severe refractory PUK requiring surgical repair of corneal perforation"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "2 mg/day",
          "frequency": null,
          "duration": "18 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "2 weeks",
          "duration_of_response": "18 months (ongoing)",
          "effect_size_description": "Complete resolution of corneal ulceration and achievement of joint remission (DAS28-CRP improved from 4.1 to 2.1)",
          "primary_endpoint": "Ocular and joint disease remission",
          "endpoint_result": "Complete ocular and joint remission achieved",
          "durability_signal": null,
          "efficacy_summary": "Patient achieved complete ocular and joint remission within 2 weeks of baricitinib initiation. No new episodes of corneal ulcers occurred during 18 months of follow-up, with sustained disease control."
        },
        "safety": {
          "adverse_events": [
            "mild alopecia"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Treatment was well tolerated with only mild alopecia reported as an adverse effect. No serious adverse effects or signs of disease reactivation occurred during 18 months of treatment.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "18 months",
        "key_findings": "Baricitinib demonstrated rapid and sustained efficacy in severe refractory PUK with corneal perforation, achieving complete remission within 2 weeks with excellent safety profile.",
        "extraction_timestamp": "2025-12-05T19:25:13.132727",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "Peripheral Ulcerative Keratitis",
        "epidemiology": {
          "us_prevalence_estimate": null,
          "us_incidence_estimate": "0.2 to 3 per million population per year",
          "global_prevalence": null,
          "patient_population_size": 838,
          "prevalence_source": "Review of Ophthalmology",
          "prevalence_source_url": "https://www.reviewofophthalmology.com/article/treating-peripheral-ulcerative-keratitis",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Prednisone (prednisone)",
              "drug_class": "Corticosteroid",
              "efficacy_range": "70-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 2000.0,
              "line_of_therapy": null,
              "notes": "FDA approved corticosteroid, first-line systemic therapy"
            },
            {
              "drug_name": "Methylprednisolone (methylprednisolone)",
              "drug_class": "Corticosteroid",
              "efficacy_range": "70-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 3000.0,
              "line_of_therapy": null,
              "notes": "FDA approved corticosteroid, used for pulse therapy"
            },
            {
              "drug_name": "Cyclosporine (cyclosporine)",
              "drug_class": "Immunosuppressant",
              "efficacy_range": "60-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 8000.0,
              "line_of_therapy": null,
              "notes": "FDA approved immunosuppressant, steroid-sparing agent"
            },
            {
              "drug_name": "Azathioprine (azathioprine)",
              "drug_class": "Immunosuppressant",
              "efficacy_range": "50-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 1500.0,
              "line_of_therapy": null,
              "notes": "FDA approved immunosuppressant, steroid-sparing agent"
            },
            {
              "drug_name": "Mycophenolate (mycophenolate)",
              "drug_class": "Immunosuppressant",
              "efficacy_range": "55-65%",
              "efficacy_pct": null,
              "annual_cost_usd": 12000.0,
              "line_of_therapy": null,
              "notes": "FDA approved immunosuppressant, alternative steroid-sparing agent"
            },
            {
              "drug_name": "Humira (adalimumab)",
              "drug_class": "TNF Inhibitor",
              "efficacy_range": "65-75%",
              "efficacy_pct": null,
              "annual_cost_usd": 80000.0,
              "line_of_therapy": null,
              "notes": "FDA approved for RA and uveitis, used off-label for severe cases"
            },
            {
              "drug_name": "Enbrel (etanercept)",
              "drug_class": "TNF Inhibitor",
              "efficacy_range": "60-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 75000.0,
              "line_of_therapy": null,
              "notes": "FDA approved for RA, used off-label for refractory cases"
            },
            {
              "drug_name": "Cyclophosphamide (cyclophosphamide)",
              "drug_class": "Alkylating Agent",
              "efficacy_range": "70-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 5000.0,
              "line_of_therapy": null,
              "notes": "FDA approved immunosuppressant, reserved for severe cases"
            }
          ],
          "approved_drug_names": [
            "Prednisone (prednisone)",
            "Methylprednisolone (methylprednisolone)",
            "Cyclosporine (cyclosporine)",
            "Azathioprine (azathioprine)",
            "Mycophenolate (mycophenolate)",
            "Humira (adalimumab)",
            "Enbrel (etanercept)",
            "Cyclophosphamide (cyclophosphamide)"
          ],
          "num_approved_drugs": 8,
          "num_pipeline_therapies": 0,
          "pipeline_details": null,
          "avg_annual_cost_usd": 23188.0,
          "treatment_paradigm": "Stepwise approach starting with systemic corticosteroids for acute inflammation, followed by steroid-sparing immunosuppressants (cyclosporine, azathioprine, mycophenolate) for maintenance. TNF inhibitors and cyclophosphamide reserved for severe or refractory cases. Treatment of underlying systemic autoimmune disease is essential.",
          "unmet_need": true,
          "unmet_need_description": "Significant unmet need exists as PUK is a sight-threatening condition with no specific FDA-approved therapies for this indication. Current treatments are repurposed from other autoimmune conditions, and many patients require prolonged immunosuppression with associated side effects. Risk of corneal perforation and vision loss remains high despite treatment.",
          "competitive_landscape": "Treatment relies on repurposed immunosuppressants and biologics approved for other autoimmune conditions, with corticosteroids and traditional DMARDs forming the backbone of therapy. Significant unmet need exists for PUK-specific therapies given the sight-threatening nature and limited treatment options for refractory cases.",
          "soc_source": "NCBI StatPearls and Medscape clinical references"
        },
        "market_size_estimate": "$19M",
        "market_size_usd": 19431544.0,
        "growth_rate": "5-8% CAGR (high unmet need)"
      },
      "scores": {
        "clinical_signal": 10.0,
        "evidence_quality": 4.3,
        "market_opportunity": 5.7,
        "overall_priority": 7.5,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 10.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "followup_duration": 10.0
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 10.0,
        "market_breakdown": {
          "competitors": 3.0,
          "market_size": 4.0,
          "unmet_need": 10.0
        },
        "competitors_score": 3.0,
        "market_size_score": 4.0,
        "unmet_need_score": 10.0
      },
      "rank": 8
    },
    {
      "extraction": {
        "source": {
          "pmid": "41239432",
          "doi": "10.1186/s13075-025-03675-9",
          "url": "https://pubmed.ncbi.nlm.nih.gov/41239432/",
          "title": "Baricitinib could improve the prognosis of anti-MDA5 antibody positive dermatomyositis associated interstitial lung disease.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Anti-MDA5 antibody positive dermatomyositis associated interstitial lung disease",
        "disease_normalized": "Dermatomyositis",
        "is_off_label": true,
        "evidence_level": "Retrospective Study",
        "patient_population": {
          "n_patients": 39,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "glucocorticoids",
            "conventional immunosuppressants",
            "calcineurin inhibitors",
            "mycophenolate mofetil",
            "cyclophosphamide"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "39 adult patients (71.8% female) with MDA5+ dermatomyositis-associated interstitial lung disease, mean age 47.6\u00b111.5 years, median disease duration 4.5 months"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "not specified",
          "frequency": null,
          "duration": "minimum 1 month",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "31/39 (79.5%)",
          "responders_n": 31,
          "responders_pct": 79.5,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "HRCT score decreased from 115 to 97.5, FVC improved from 76.44% to 90.73%, serum ferritin decreased from 739.9 to 56.3 ng/ml",
          "primary_endpoint": "clinical improvement including skin manifestations and respiratory symptoms",
          "endpoint_result": "31 patients (79.5%) had clinical improvement",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib showed significant improvement in clinical symptoms, lung function, and inflammatory markers in 79.5% of patients. Six-month survival was superior in the baricitinib group compared to controls (87.2% vs 70%). First-line baricitinib use showed even better survival outcomes compared to conventional therapy (84.6% vs 52.9%)."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Safety outcomes were not explicitly reported in detail in this retrospective study. No specific adverse events were mentioned in the available text.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "6 months",
        "key_findings": "Baricitinib demonstrated significant clinical improvement in 79.5% of MDA5+ dermatomyositis-ILD patients with improved survival outcomes, particularly when used as first-line therapy.",
        "extraction_timestamp": "2025-12-05T19:20:15.456488",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "Dermatomyositis",
        "epidemiology": {
          "us_prevalence_estimate": "21.4 per 100,000",
          "us_incidence_estimate": "15.2 per million person-years",
          "global_prevalence": null,
          "patient_population_size": 71690,
          "prevalence_source": "Arthritis Care & Research",
          "prevalence_source_url": "https://www.dermatologyadvisor.com/news/incidence-prevalence-and-mortality-of-dermatomyositis-in-adults-determined/",
          "trend": "increasing"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Octagam 10% (immune globulin intravenous)",
              "drug_class": "Intravenous Immunoglobulin",
              "efficacy_range": "60-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 75000.0,
              "line_of_therapy": null,
              "notes": "FDA approved for dermatomyositis in adults (July 2021)"
            },
            {
              "drug_name": "Prednisone (prednisone)",
              "drug_class": "Corticosteroid",
              "efficacy_range": "50-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 2000.0,
              "line_of_therapy": null,
              "notes": "Standard first-line therapy, off-label use"
            },
            {
              "drug_name": "Methotrexate (methotrexate)",
              "drug_class": "DMARD/Immunosuppressant",
              "efficacy_range": "40-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 5000.0,
              "line_of_therapy": null,
              "notes": "Steroid-sparing agent, off-label use"
            },
            {
              "drug_name": "Azathioprine (azathioprine)",
              "drug_class": "Immunosuppressant",
              "efficacy_range": "40-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 3000.0,
              "line_of_therapy": null,
              "notes": "Steroid-sparing agent, off-label use"
            },
            {
              "drug_name": "Sirolimus (sirolimus)",
              "drug_class": "mTOR Inhibitor",
              "efficacy_range": "30-50%",
              "efficacy_pct": null,
              "annual_cost_usd": 25000.0,
              "line_of_therapy": null,
              "notes": "Off-label use for refractory cases"
            }
          ],
          "approved_drug_names": [
            "Octagam 10% (immune globulin intravenous)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 0,
          "pipeline_details": null,
          "avg_annual_cost_usd": 22000.0,
          "treatment_paradigm": "First-line treatment typically involves corticosteroids, followed by steroid-sparing immunosuppressants like methotrexate or azathioprine. IVIG (Octagam 10%) is reserved for refractory cases or when conventional therapy fails.",
          "unmet_need": true,
          "unmet_need_description": "Dermatomyositis has significant unmet need with only one FDA-approved therapy (IVIG), limited treatment options, variable response rates, and reliance on off-label immunosuppressants with significant side effects. Many patients experience incomplete responses or disease progression despite treatment.",
          "competitive_landscape": "Dermatomyositis has a very limited treatment landscape with only Octagam 10% (IVIG) FDA-approved specifically for this indication as of 2021. The field relies heavily on off-label corticosteroids and immunosuppressants, creating substantial unmet need for effective disease-modifying therapies with better safety profiles.",
          "soc_source": "FDA Orphan Drug Database and Medscape Dermatomyositis Treatment Guidelines - https://www.accessdata.fda.gov/scripts/opdlisting/oopd/"
        },
        "market_size_estimate": "$1.6B",
        "market_size_usd": 1577180000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)"
      },
      "scores": {
        "clinical_signal": 6.5,
        "evidence_quality": 8.3,
        "market_opportunity": 8.3,
        "overall_priority": 7.4,
        "clinical_breakdown": {
          "response_rate": 8.0,
          "safety_profile": 5.0
        },
        "response_rate_score": 8.0,
        "safety_profile_score": 5.0,
        "evidence_breakdown": {
          "sample_size": 8.0,
          "publication_venue": 10.0,
          "followup_duration": 7.0
        },
        "sample_size_score": 8.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 7.0,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 9
    },
    {
      "extraction": {
        "source": {
          "pmid": "36389811",
          "doi": "10.3389/fimmu.2022.1008392",
          "url": "https://www.semanticscholar.org/paper/23791402d1f9cc42cfe6cadf0283618cb0b22093",
          "title": "Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "livedoid vasculopathy",
        "disease_normalized": "Livedoid Vasculopathy",
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 8,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "corticosteroids",
            "thalidomide",
            "tripterygium glycosides",
            "rivaroxaban",
            "enoxaparin",
            "aspirin",
            "compound glycyrrhizin",
            "Chinese traditional anti-inflammatory drugs"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "8 patients (mean age 21.1 \u00b1 9.1 years, including 2 pediatric patients) with refractory livedoid vasculopathy resistant to conventional treatments"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "2 mg/day",
          "frequency": null,
          "duration": "3-13 weeks to remission",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "6/8 (75%)",
          "responders_n": 6,
          "responders_pct": 75.0,
          "time_to_response": "mean remission time of 7.75 \u00b1 3.45 weeks (range 3-13 weeks)",
          "duration_of_response": null,
          "effect_size_description": "statistically significant improvement with large effect size, clinical score reduction of approximately 5.6 points on 8-point scale",
          "primary_endpoint": "clinical score reduction (0-8 scale measuring pain, ulceration, and erythema)",
          "endpoint_result": "mean clinical scores decreased from 7.0 \u00b1 1.6 to 1.4 \u00b1 1.2 (P < 0.01)",
          "durability_signal": null,
          "efficacy_summary": "All 8 patients showed significant clinical improvement with statistically significant reduction in clinical scores. Six patients achieved remission (clinical score \u22642) with improvements in erythema, ulceration, and pain."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse events were reported in any patient during follow-up. Treatment was well-tolerated with no severe side effects, including in the two pediatric patients.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "10-28 weeks (average 16.50 weeks)",
        "key_findings": "Baricitinib demonstrated significant efficacy in treating refractory livedoid vasculopathy with 100% clinical improvement rate and 75% remission rate, with excellent safety profile.",
        "extraction_timestamp": "2025-12-05T19:24:01.945654",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "Livedoid Vasculopathy",
        "epidemiology": {
          "us_prevalence_estimate": "1 in 100,000",
          "us_incidence_estimate": "1 in 100,000 per year",
          "global_prevalence": null,
          "patient_population_size": 3350,
          "prevalence_source": "eMedicine/Medscape",
          "prevalence_source_url": "https://emedicine.medscape.com/article/1082675-overview",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Rivaroxaban (rivaroxaban)",
              "drug_class": "Direct oral anticoagulant (DOAC)",
              "efficacy_range": "70-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 3600.0,
              "line_of_therapy": null,
              "notes": "Off-label, German S1 guideline first-line therapy"
            },
            {
              "drug_name": "Low-molecular-weight heparins",
              "drug_class": "Anticoagulant",
              "efficacy_range": "60-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 2400.0,
              "line_of_therapy": null,
              "notes": "Off-label, guideline-recommended first-line therapy"
            },
            {
              "drug_name": "Tofacitinib (tofacitinib)",
              "drug_class": "JAK inhibitor",
              "efficacy_range": "60-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 70000.0,
              "line_of_therapy": null,
              "notes": "Off-label, case reports show effectiveness"
            },
            {
              "drug_name": "Warfarin (warfarin)",
              "drug_class": "Vitamin K antagonist",
              "efficacy_range": "50-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 1200.0,
              "line_of_therapy": null,
              "notes": "Off-label, traditional anticoagulant option"
            },
            {
              "drug_name": "Direct oral anticoagulants",
              "drug_class": "DOAC",
              "efficacy_range": "65-75%",
              "efficacy_pct": null,
              "annual_cost_usd": 4000.0,
              "line_of_therapy": null,
              "notes": "Off-label, guideline-recommended"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 0,
          "pipeline_details": null,
          "avg_annual_cost_usd": 16240.0,
          "treatment_paradigm": "German S1 guideline recommends anticoagulation as first-line therapy, primarily with DOACs like rivaroxaban or low-molecular-weight heparins. JAK inhibitors and biologics are emerging as second-line options for refractory cases.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved treatments exist for livedoid vasculopathy, making off-label therapy the only option. Long-term treatment is usually necessary and some patients continue to have ulcers despite treatment, significantly impacting quality of life.",
          "competitive_landscape": "Livedoid vasculopathy has no approved treatments, with all therapy being off-label anticoagulation primarily using rivaroxaban or low-molecular-weight heparins per German guidelines. Significant unmet need exists as patients require long-term therapy with variable response rates and continued ulceration despite treatment.",
          "soc_source": "German S1 guideline and PubMed study - https://pubmed.ncbi.nlm.nih.gov/41264385/"
        },
        "market_size_estimate": "$54M",
        "market_size_usd": 54404000.0,
        "growth_rate": "5-8% CAGR (high unmet need)"
      },
      "scores": {
        "clinical_signal": 9.0,
        "evidence_quality": 3.0,
        "market_opportunity": 8.3,
        "overall_priority": 7.3,
        "clinical_breakdown": {
          "response_rate": 8.0,
          "safety_profile": 10.0
        },
        "response_rate_score": 8.0,
        "safety_profile_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 4.0,
          "publication_venue": 2.0,
          "followup_duration": 3.0
        },
        "sample_size_score": 4.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 3.0,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 5.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 5.0,
        "unmet_need_score": 10.0
      },
      "rank": 10
    },
    {
      "extraction": {
        "source": {
          "pmid": "37304255",
          "doi": "10.3389/fimmu.2023.1187584",
          "url": "https://pubmed.ncbi.nlm.nih.gov/37304255/",
          "title": "Clinical experience and safety of Janus kinase inhibitors in giant cell arteritis: a retrospective case series from Sweden.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Giant Cell Arteritis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 15,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "corticosteroids",
            "tocilizumab",
            "methotrexate",
            "infliximab"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Mean age 70.1 years (range 61-80), 60% women, all Caucasian, with GCA diagnosed by ACR criteria and/or imaging"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "baricitinib 3.86 mg daily (range 2-4 mg), tofacitinib 10 mg daily",
          "frequency": null,
          "duration": "mean 19 months (range 6-38 months)",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "11/15 (73%)",
          "responders_n": 11,
          "responders_pct": 73.0,
          "time_to_response": "3 months",
          "duration_of_response": "sustained through follow-up",
          "effect_size_description": "Significant reductions in CRP, ESR, and prednisolone dose requirements",
          "primary_endpoint": "CRP reduction",
          "endpoint_result": "Significant CRP reduction at 3 months (p=0.02) and 6 months (p=0.02)",
          "durability_signal": null,
          "efficacy_summary": "JAK inhibitors showed significant efficacy in treating GCA with sustained reductions in inflammatory markers and steroid-sparing effects. No GCA relapses were observed during treatment, and 73% of patients achieved therapeutic benefit at 6 months."
        },
        "safety": {
          "adverse_events": [
            "minor blood cell count changes"
          ],
          "serious_adverse_events": [
            "bacteremia (Enterococcus faecalis)",
            "Aspergillus fumigatus infection"
          ],
          "sae_count": 2,
          "sae_percentage": 13.3,
          "discontinuations_n": 3,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "sustained remission"
          ],
          "safety_summary": "Two patients experienced serious infections but JAK inhibitor therapy was retained or reintroduced after recovery. No cases of malignancy, gastrointestinal perforation, liver enzyme elevation, or herpes zoster were observed.",
          "safety_profile": "Acceptable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "mean 19 months",
        "key_findings": "JAK inhibitors demonstrated strong efficacy in steroid-refractory GCA with acceptable safety profile and significant steroid-sparing effects.",
        "extraction_timestamp": "2025-12-05T19:19:27.912822",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "Giant Cell Arteritis",
        "epidemiology": {
          "us_prevalence_estimate": "105.6 per 100,000 Medicare beneficiaries aged 65+",
          "us_incidence_estimate": "24.7 per 100,000 Medicare beneficiaries aged 65+ annually",
          "global_prevalence": null,
          "patient_population_size": 58240,
          "prevalence_source": "ACR Abstract - Medicare Fee-for-Service study 2014-2019",
          "prevalence_source_url": "https://acrabstracts.org/abstract/prevalence-and-incidence-of-giant-cell-arteritis-among-medicare-fee-for-service-beneficiaries-united-states-2014-2019/",
          "trend": "stable"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Actemra (tocilizumab)",
              "drug_class": "IL-6 receptor antagonist",
              "efficacy_range": "60-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 65000.0,
              "line_of_therapy": null,
              "notes": "First and only FDA-approved drug specifically for GCA"
            },
            {
              "drug_name": "Prednisone",
              "drug_class": "Corticosteroid",
              "efficacy_range": "80-90%",
              "efficacy_pct": null,
              "annual_cost_usd": 2000.0,
              "line_of_therapy": null,
              "notes": "Standard of care, off-label use for GCA"
            },
            {
              "drug_name": "Prednisolone",
              "drug_class": "Corticosteroid",
              "efficacy_range": "80-90%",
              "efficacy_pct": null,
              "annual_cost_usd": 2000.0,
              "line_of_therapy": null,
              "notes": "Standard of care, off-label use for GCA"
            },
            {
              "drug_name": "Methotrexate",
              "drug_class": "DMARD",
              "efficacy_range": "40-50%",
              "efficacy_pct": null,
              "annual_cost_usd": 3000.0,
              "line_of_therapy": null,
              "notes": "Steroid-sparing agent, off-label use"
            },
            {
              "drug_name": "Humira (adalimumab)",
              "drug_class": "TNF inhibitor",
              "efficacy_range": "30-40%",
              "efficacy_pct": null,
              "annual_cost_usd": 75000.0,
              "line_of_therapy": null,
              "notes": "Used in refractory cases, off-label"
            }
          ],
          "approved_drug_names": [
            "Actemra (tocilizumab)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 0,
          "pipeline_details": null,
          "avg_annual_cost_usd": 29400.0,
          "treatment_paradigm": "First-line treatment with high-dose corticosteroids followed by gradual tapering. Tocilizumab can be used as steroid-sparing therapy or following steroid discontinuation. Methotrexate and TNF inhibitors may be considered in refractory cases.",
          "unmet_need": true,
          "unmet_need_description": "Only one FDA-approved drug available. High reliance on corticosteroids with significant long-term side effects. Limited options for steroid-sparing therapy and refractory cases.",
          "competitive_landscape": "Actemra (tocilizumab) is the only FDA-approved treatment for giant cell arteritis, with standard care still heavily reliant on corticosteroids. Significant unmet need exists for additional steroid-sparing therapies and treatments for refractory cases.",
          "soc_source": "Medscape Giant Cell Arteritis Medication and FDA Actemra approval documentation - https://emedicine.medscape.com/article/332483-medication"
        },
        "market_size_estimate": "$1.7B",
        "market_size_usd": 1712256000.0,
        "growth_rate": "3-5% CAGR (stable prevalence)"
      },
      "scores": {
        "clinical_signal": 6.0,
        "evidence_quality": 8.7,
        "market_opportunity": 8.3,
        "overall_priority": 7.2,
        "clinical_breakdown": {
          "response_rate": 8.0,
          "safety_profile": 4.0
        },
        "response_rate_score": 8.0,
        "safety_profile_score": 4.0,
        "evidence_breakdown": {
          "sample_size": 6.0,
          "publication_venue": 10.0,
          "followup_duration": 10.0
        },
        "sample_size_score": 6.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 10.0,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 11
    },
    {
      "extraction": {
        "source": {
          "pmid": "39666590",
          "doi": "10.12659/AJCR.945068",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39666590/",
          "title": "Alopecia Areata Following the Use of Belimumab in a Patient with Systemic Lupus Erythematosus and Arthritis Who Responded Well to Baricitinib: A Case Report.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Systemic Lupus Erythematosus with Arthritis",
        "disease_normalized": "Systemic Lupus Erythematosus",
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "conventional drugs",
            "belimumab",
            "systemic steroids",
            "local steroid injections",
            "azathioprine",
            "methotrexate",
            "mycophenolate"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "54-year-old Saudi female with SLE presenting with mucocutaneous symptoms and arthritis, positive ANA and anti-dsDNA"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "significant improvement",
          "primary_endpoint": "improvement in alopecia totalis and arthritis",
          "endpoint_result": "significant improvement in alopecia totalis and arthritis",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib resulted in significant improvement in both alopecia totalis and arthritis symptoms in this SLE patient. The patient had failed multiple prior treatments including belimumab, steroids, and conventional DMARDs."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse events were reported with baricitinib treatment in this case report.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Baricitinib effectively treated both alopecia totalis and arthritis in an SLE patient who had failed multiple conventional treatments including belimumab.",
        "extraction_timestamp": "2025-12-05T19:21:11.408103",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "Systemic Lupus Erythematosus",
        "epidemiology": {
          "us_prevalence_estimate": "72.8 per 100,000 population",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 204295,
          "prevalence_source": "CDC National Lupus Registry network",
          "prevalence_source_url": "https://pubmed.ncbi.nlm.nih.gov/33474834/",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Benlysta (belimumab)",
              "drug_class": "B-lymphocyte stimulator inhibitor",
              "efficacy_range": "50-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 35000.0,
              "line_of_therapy": null,
              "notes": "FDA approved for SLE and lupus nephritis"
            },
            {
              "drug_name": "Ojjaara (obinutuzumab)",
              "drug_class": "Anti-CD20 monoclonal antibody",
              "efficacy_range": "55-65%",
              "efficacy_pct": null,
              "annual_cost_usd": 45000.0,
              "line_of_therapy": null,
              "notes": "FDA approved for active lupus nephritis"
            },
            {
              "drug_name": "Hydroxychloroquine",
              "drug_class": "Antimalarial",
              "efficacy_range": "40-50%",
              "efficacy_pct": null,
              "annual_cost_usd": 2000.0,
              "line_of_therapy": null,
              "notes": "Off-label, standard of care"
            },
            {
              "drug_name": "Methotrexate",
              "drug_class": "DMARD",
              "efficacy_range": "45-55%",
              "efficacy_pct": null,
              "annual_cost_usd": 3000.0,
              "line_of_therapy": null,
              "notes": "Off-label immunosuppressant"
            },
            {
              "drug_name": "Azathioprine (Imuran)",
              "drug_class": "Immunosuppressant",
              "efficacy_range": "40-50%",
              "efficacy_pct": null,
              "annual_cost_usd": 5000.0,
              "line_of_therapy": null,
              "notes": "Off-label for severe lupus"
            },
            {
              "drug_name": "Mycophenolate (CellCept)",
              "drug_class": "Immunosuppressant",
              "efficacy_range": "50-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 8000.0,
              "line_of_therapy": null,
              "notes": "Off-label, commonly used for lupus nephritis"
            },
            {
              "drug_name": "Rituximab (Rituxan)",
              "drug_class": "Anti-CD20 monoclonal antibody",
              "efficacy_range": "45-55%",
              "efficacy_pct": null,
              "annual_cost_usd": 40000.0,
              "line_of_therapy": null,
              "notes": "Off-label biologic"
            },
            {
              "drug_name": "Cyclophosphamide",
              "drug_class": "Alkylating agent",
              "efficacy_range": "55-65%",
              "efficacy_pct": null,
              "annual_cost_usd": 6000.0,
              "line_of_therapy": null,
              "notes": "Off-label for severe manifestations"
            }
          ],
          "approved_drug_names": [
            "Benlysta (belimumab)",
            "Ojjaara (obinutuzumab)"
          ],
          "num_approved_drugs": 2,
          "num_pipeline_therapies": 5,
          "pipeline_details": "Several anti-CD20 antibodies, JAK inhibitors, and novel B-cell targeted therapies in Phase 2-3 trials for lupus nephritis and SLE",
          "avg_annual_cost_usd": 18000.0,
          "treatment_paradigm": "Stepwise approach starting with antimalarials and NSAIDs, progressing to immunosuppressants and biologics for severe disease, with corticosteroids for flares",
          "unmet_need": true,
          "unmet_need_description": "Only 2 FDA-approved drugs for SLE, most treatments are off-label, significant reliance on corticosteroids with long-term toxicity, and many patients have inadequate response to current therapies",
          "competitive_landscape": "SLE has limited FDA-approved options with only Benlysta and obinutuzumab specifically approved, relying heavily on off-label immunosuppressants and antimalarials. Significant unmet need exists given the chronic nature of disease and limited efficacy of current treatments.",
          "soc_source": "Medscape eMedicine and Drugs.com - https://emedicine.medscape.com/article/332244-treatment"
        },
        "market_size_estimate": "$3.7B",
        "market_size_usd": 3677310000.0,
        "growth_rate": "5-8% CAGR (high unmet need)"
      },
      "scores": {
        "clinical_signal": 7.5,
        "evidence_quality": 5.3,
        "market_opportunity": 8.3,
        "overall_priority": 7.2,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 5.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 5.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "followup_duration": 5.0
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 5.0,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 12
    },
    {
      "extraction": {
        "source": {
          "pmid": "37010773",
          "doi": "10.1007/s40268-023-00417-7",
          "url": "https://www.semanticscholar.org/paper/8552fa1bffd375e41208d1b21c50d6d9460b75f3",
          "title": "Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still\u2019s Disease",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Adult-onset Still's disease (AOSD)",
        "disease_normalized": "Adult-onset Still's Disease",
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 7,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "glucocorticoids",
            "conventional DMARDs",
            "NSAIDs",
            "tocilizumab"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "7 female patients with refractory AOSD, median age 31 years, median disease duration 11 months"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg once daily",
          "frequency": null,
          "duration": "2-18 months follow-up",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "6/7 (85.7%)",
          "responders_n": 6,
          "responders_pct": 85.7,
          "time_to_response": "1-5 months",
          "duration_of_response": "sustained through follow-up period",
          "effect_size_description": "significant reduction in systemic score, CRP (p=0.0165), ferritin (p=0.0047), and prednisolone dose from 35.7\u00b115.1 to 5.8\u00b14.7 mg/day",
          "primary_endpoint": "systemic score reduction and clinical improvement",
          "endpoint_result": "significant systemic score reduction at 3 months (p=0.0216), 6 months (p=0.0007), and last follow-up (p=0.0007)",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib provided rapid and durable clinical improvement in 6/7 patients with refractory AOSD, with significant reductions in disease activity scores, inflammatory markers, and steroid requirements. Five patients remained symptom-free at last follow-up."
        },
        "safety": {
          "adverse_events": [
            "abnormal lipid parameters",
            "leukopenia"
          ],
          "serious_adverse_events": [
            "progressive macrophage activation syndrome"
          ],
          "sae_count": 1,
          "sae_percentage": 14.3,
          "discontinuations_n": 1,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "progressive macrophage activation syndrome"
          ],
          "safety_summary": "Treatment was generally well tolerated with mild lipid abnormalities being the most common adverse event. One patient discontinued due to progressive macrophage activation syndrome.",
          "safety_profile": "Acceptable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "2-18 months",
        "key_findings": "Baricitinib showed strong efficacy in refractory AOSD with 85.7% response rate and significant steroid-sparing effects, with acceptable safety profile.",
        "extraction_timestamp": "2025-12-05T19:23:49.880656",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "Adult-onset Still's Disease",
        "epidemiology": {
          "us_prevalence_estimate": "1-9/100,000 population",
          "us_incidence_estimate": "0.16-0.4 per 100,000 adults",
          "global_prevalence": null,
          "patient_population_size": 16750,
          "prevalence_source": "Orphanet",
          "prevalence_source_url": null,
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Ilaris (canakinumab)",
              "drug_class": "IL-1 inhibitor",
              "efficacy_range": "70-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 150000.0,
              "line_of_therapy": null,
              "notes": "FDA-approved for Adult-Onset Still's Disease and SJIA (2020)"
            },
            {
              "drug_name": "Kineret (anakinra)",
              "drug_class": "IL-1 receptor antagonist",
              "efficacy_range": "65-75%",
              "efficacy_pct": null,
              "annual_cost_usd": 50000.0,
              "line_of_therapy": null,
              "notes": "Orphan designation but not FDA approved for Still's disease; widely used off-label"
            },
            {
              "drug_name": "Actemra (tocilizumab)",
              "drug_class": "IL-6 inhibitor",
              "efficacy_range": "60-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 60000.0,
              "line_of_therapy": null,
              "notes": "Off-label use; FDA-approved for related conditions including SJIA"
            },
            {
              "drug_name": "Gamifant (emapalumab)",
              "drug_class": "IFN-gamma inhibitor",
              "efficacy_range": "50-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 200000.0,
              "line_of_therapy": null,
              "notes": "FDA-approved for MAS in Still's disease (2025)"
            },
            {
              "drug_name": "Corticosteroids",
              "drug_class": "Corticosteroid",
              "efficacy_range": "40-50%",
              "efficacy_pct": null,
              "annual_cost_usd": 2000.0,
              "line_of_therapy": null,
              "notes": "Standard first-line therapy but limited long-term efficacy"
            },
            {
              "drug_name": "Methotrexate",
              "drug_class": "DMARD",
              "efficacy_range": "30-40%",
              "efficacy_pct": null,
              "annual_cost_usd": 5000.0,
              "line_of_therapy": null,
              "notes": "Off-label use as conventional DMARD"
            }
          ],
          "approved_drug_names": [
            "Ilaris (canakinumab)",
            "Gamifant (emapalumab)"
          ],
          "num_approved_drugs": 2,
          "num_pipeline_therapies": 0,
          "pipeline_details": null,
          "avg_annual_cost_usd": 77833.0,
          "treatment_paradigm": "Corticosteroids for initial management, with biologics (particularly IL-1 inhibitors) increasingly used as first-line therapy due to superior efficacy over conventional DMARDs",
          "unmet_need": true,
          "unmet_need_description": "Limited FDA-approved options, frequent relapses, significant side effects from corticosteroids, and potential for life-threatening complications like MAS",
          "competitive_landscape": "Ilaris is the only FDA-approved biologic specifically for AOSD, with anakinra widely used off-label despite lack of FDA approval. Significant unmet need remains due to limited approved options and risk of serious complications requiring specialized treatments like emapalumab for MAS.",
          "soc_source": "FDA Orphan Drug Designations and Approvals Database - https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm"
        },
        "market_size_estimate": "$1.3B",
        "market_size_usd": 1303702750.0,
        "growth_rate": "5-8% CAGR (high unmet need)"
      },
      "scores": {
        "clinical_signal": 7.0,
        "evidence_quality": 5.3,
        "market_opportunity": 8.3,
        "overall_priority": 6.9,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 4.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 4.0,
        "evidence_breakdown": {
          "sample_size": 4.0,
          "publication_venue": 2.0,
          "followup_duration": 10.0
        },
        "sample_size_score": 4.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 10.0,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 13
    },
    {
      "extraction": {
        "source": {
          "pmid": "35578304",
          "doi": "10.1186/s13075-022-02794-x",
          "url": "https://www.semanticscholar.org/paper/87cc82cdb100f9983aa5de52c796cd26ccd616e2",
          "title": "Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "systemic lupus erythematosus",
        "disease_normalized": "Systemic Lupus Erythematosus",
        "is_off_label": true,
        "evidence_level": "Retrospective Study",
        "patient_population": {
          "n_patients": 314,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Adults with SLE, mean age 43-45 years, 94% female, disease duration 10-12 years, baseline SLEDAI-2K score ~9"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "2 mg or 4 mg daily",
          "frequency": null,
          "duration": "24 weeks",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": "as early as week 2 for 2mg dose, week 4 for 4mg dose",
          "duration_of_response": "sustained through 24 weeks",
          "effect_size_description": "rapid and sustained significant decrease in anti-dsDNA antibodies and IgG levels",
          "primary_endpoint": "median change from baseline in anti-dsDNA antibodies",
          "endpoint_result": "significant decreases in anti-dsDNA: baricitinib 2mg -29.6 IU/mL, baricitinib 4mg -15.1 IU/mL vs placebo +3.0 IU/mL at week 24",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib demonstrated rapid and sustained reductions in anti-dsDNA antibodies compared to placebo, with effects beginning at weeks 2-4 and continuing through week 24. The 4mg dose also significantly reduced IgG levels at weeks 12 and 24."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Safety outcomes were not reported in this analysis, which focused specifically on serologic biomarker changes from the phase II trial.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "24 weeks",
        "key_findings": "Baricitinib significantly reduced anti-dsDNA antibodies and IgG levels in SLE patients, suggesting potential impact on B cell activity and autoantibody production.",
        "extraction_timestamp": "2025-12-05T19:18:06.833634",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "Systemic Lupus Erythematosus",
        "epidemiology": {
          "us_prevalence_estimate": "72.8 per 100,000 population",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 204295,
          "prevalence_source": "CDC National Lupus Registry network",
          "prevalence_source_url": "https://pubmed.ncbi.nlm.nih.gov/33474834/",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Benlysta (belimumab)",
              "drug_class": "B-lymphocyte stimulator inhibitor",
              "efficacy_range": "50-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 35000.0,
              "line_of_therapy": null,
              "notes": "FDA approved for SLE and lupus nephritis"
            },
            {
              "drug_name": "Ojjaara (obinutuzumab)",
              "drug_class": "Anti-CD20 monoclonal antibody",
              "efficacy_range": "55-65%",
              "efficacy_pct": null,
              "annual_cost_usd": 45000.0,
              "line_of_therapy": null,
              "notes": "FDA approved for active lupus nephritis"
            },
            {
              "drug_name": "Hydroxychloroquine",
              "drug_class": "Antimalarial",
              "efficacy_range": "40-50%",
              "efficacy_pct": null,
              "annual_cost_usd": 2000.0,
              "line_of_therapy": null,
              "notes": "Off-label, standard of care"
            },
            {
              "drug_name": "Methotrexate",
              "drug_class": "DMARD",
              "efficacy_range": "45-55%",
              "efficacy_pct": null,
              "annual_cost_usd": 3000.0,
              "line_of_therapy": null,
              "notes": "Off-label immunosuppressant"
            },
            {
              "drug_name": "Azathioprine (Imuran)",
              "drug_class": "Immunosuppressant",
              "efficacy_range": "40-50%",
              "efficacy_pct": null,
              "annual_cost_usd": 5000.0,
              "line_of_therapy": null,
              "notes": "Off-label for severe lupus"
            },
            {
              "drug_name": "Mycophenolate (CellCept)",
              "drug_class": "Immunosuppressant",
              "efficacy_range": "50-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 8000.0,
              "line_of_therapy": null,
              "notes": "Off-label, commonly used for lupus nephritis"
            },
            {
              "drug_name": "Rituximab (Rituxan)",
              "drug_class": "Anti-CD20 monoclonal antibody",
              "efficacy_range": "45-55%",
              "efficacy_pct": null,
              "annual_cost_usd": 40000.0,
              "line_of_therapy": null,
              "notes": "Off-label biologic"
            },
            {
              "drug_name": "Cyclophosphamide",
              "drug_class": "Alkylating agent",
              "efficacy_range": "55-65%",
              "efficacy_pct": null,
              "annual_cost_usd": 6000.0,
              "line_of_therapy": null,
              "notes": "Off-label for severe manifestations"
            }
          ],
          "approved_drug_names": [
            "Benlysta (belimumab)",
            "Ojjaara (obinutuzumab)"
          ],
          "num_approved_drugs": 2,
          "num_pipeline_therapies": 5,
          "pipeline_details": "Several anti-CD20 antibodies, JAK inhibitors, and novel B-cell targeted therapies in Phase 2-3 trials for lupus nephritis and SLE",
          "avg_annual_cost_usd": 18000.0,
          "treatment_paradigm": "Stepwise approach starting with antimalarials and NSAIDs, progressing to immunosuppressants and biologics for severe disease, with corticosteroids for flares",
          "unmet_need": true,
          "unmet_need_description": "Only 2 FDA-approved drugs for SLE, most treatments are off-label, significant reliance on corticosteroids with long-term toxicity, and many patients have inadequate response to current therapies",
          "competitive_landscape": "SLE has limited FDA-approved options with only Benlysta and obinutuzumab specifically approved, relying heavily on off-label immunosuppressants and antimalarials. Significant unmet need exists given the chronic nature of disease and limited efficacy of current treatments.",
          "soc_source": "Medscape eMedicine and Drugs.com - https://emedicine.medscape.com/article/332244-treatment"
        },
        "market_size_estimate": "$3.7B",
        "market_size_usd": 3677310000.0,
        "growth_rate": "5-8% CAGR (high unmet need)"
      },
      "scores": {
        "clinical_signal": 7.0,
        "evidence_quality": 5.0,
        "market_opportunity": 8.3,
        "overall_priority": 6.8,
        "clinical_breakdown": {
          "response_rate": 9.0,
          "safety_profile": 5.0
        },
        "response_rate_score": 9.0,
        "safety_profile_score": 5.0,
        "evidence_breakdown": {
          "sample_size": 10.0,
          "publication_venue": 2.0,
          "followup_duration": 3.0
        },
        "sample_size_score": 10.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 3.0,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 14
    },
    {
      "extraction": {
        "source": {
          "pmid": "38519108",
          "doi": "10.1136/rmdopen-2023-003985",
          "url": "https://pubmed.ncbi.nlm.nih.gov/38519108/",
          "title": "Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Takayasu arteritis",
        "disease_normalized": "Takayasu Arteritis",
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 10,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "glucocorticoids",
            "methotrexate",
            "leflunomide",
            "mycophenolate mofetil",
            "tacrolimus",
            "TNF inhibitors",
            "tocilizumab",
            "secukinumab",
            "tofacitinib"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Refractory Takayasu arteritis patients, median age 28 years, 9 female/1 male, median disease duration 50 months"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg daily",
          "frequency": null,
          "duration": "average follow-up 15.3 months (range 4-31)",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "6/10 (60%)",
          "responders_n": 6,
          "responders_pct": 60.0,
          "time_to_response": "6 months",
          "duration_of_response": "4/10 (40%) patients maintained overall treatment response during follow-up",
          "effect_size_description": "60% response rate at 6 months, 40% maintained response long-term, 80% of patients tapered or maintained same GC dose",
          "primary_endpoint": "overall treatment response rate at 6 months",
          "endpoint_result": "6/10 (60%) patients had overall treatment response at 6 months",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib 4 mg daily achieved overall treatment response in 60% of refractory TAK patients at 6 months. During average 15.3 months follow-up, 40% maintained response and 80% were able to taper or maintain glucocorticoid doses."
        },
        "safety": {
          "adverse_events": [
            "liver dysfunction"
          ],
          "serious_adverse_events": [
            "liver dysfunction"
          ],
          "sae_count": 1,
          "sae_percentage": 10.0,
          "discontinuations_n": 1,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "liver dysfunction"
          ],
          "safety_summary": "Baricitinib was well tolerated with only one patient (10%) discontinuing due to liver dysfunction. No other severe adverse events were reported during the study period.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": "average 15.3 months (range 4-31)",
        "key_findings": "Baricitinib 4 mg daily is effective for refractory Takayasu arteritis with 60% response rate and good tolerability profile.",
        "extraction_timestamp": "2025-12-05T19:20:30.148661",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "Takayasu Arteritis",
        "epidemiology": {
          "us_prevalence_estimate": "8.4 per million population",
          "us_incidence_estimate": "2.6 cases per million per year",
          "global_prevalence": null,
          "patient_population_size": 2814,
          "prevalence_source": "The Journal of Rheumatology",
          "prevalence_source_url": "https://www.jrheum.org/content/jrheum/48/6/952.full.pdf",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Prednisone (prednisone)",
              "drug_class": "Corticosteroid",
              "efficacy_range": "70-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 2000.0,
              "line_of_therapy": null,
              "notes": "Off-label, first-line standard of care"
            },
            {
              "drug_name": "Actemra (tocilizumab)",
              "drug_class": "IL-6 inhibitor",
              "efficacy_range": "60-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 65000.0,
              "line_of_therapy": null,
              "notes": "FDA-approved for giant cell arteritis"
            },
            {
              "drug_name": "Methotrexate (methotrexate)",
              "drug_class": "DMARD",
              "efficacy_range": "50-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 3000.0,
              "line_of_therapy": null,
              "notes": "Off-label, steroid-sparing agent"
            },
            {
              "drug_name": "Humira (adalimumab)",
              "drug_class": "TNF inhibitor",
              "efficacy_range": "50-65%",
              "efficacy_pct": null,
              "annual_cost_usd": 80000.0,
              "line_of_therapy": null,
              "notes": "FDA-approved for RA and other autoimmune conditions"
            },
            {
              "drug_name": "Azathioprine (azathioprine)",
              "drug_class": "Immunosuppressant",
              "efficacy_range": "45-55%",
              "efficacy_pct": null,
              "annual_cost_usd": 2500.0,
              "line_of_therapy": null,
              "notes": "Off-label, for refractory cases"
            },
            {
              "drug_name": "Cyclophosphamide (cyclophosphamide)",
              "drug_class": "Cytotoxic agent",
              "efficacy_range": "60-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 8000.0,
              "line_of_therapy": null,
              "notes": "Off-label, reserved for severe refractory disease"
            }
          ],
          "approved_drug_names": [
            "Actemra (tocilizumab)",
            "Humira (adalimumab)"
          ],
          "num_approved_drugs": 2,
          "num_pipeline_therapies": 1,
          "pipeline_details": "Upadacitinib (JAK inhibitor) recently received FDA approval for giant cell arteritis in 2025 and may be considered for Takayasu arteritis",
          "avg_annual_cost_usd": 35000.0,
          "treatment_paradigm": "Corticosteroids as first-line therapy with gradual taper, combined with DMARDs for steroid-sparing effect. Biologics like tocilizumab or TNF inhibitors used for active disease or refractory cases. Cytotoxic agents reserved for severe, treatment-resistant disease.",
          "unmet_need": true,
          "unmet_need_description": "Limited FDA-approved therapies specifically for Takayasu arteritis, reliance on off-label use of drugs approved for related conditions, significant steroid dependence and associated toxicity, and substantial number of patients with refractory disease requiring multiple immunosuppressive agents",
          "competitive_landscape": "Only tocilizumab has FDA approval for the related condition giant cell arteritis, with most treatments being off-label use of corticosteroids, DMARDs, and biologics approved for other autoimmune conditions. Significant unmet need exists due to limited specific approvals, steroid toxicity, and refractory disease in many patients.",
          "soc_source": "Medscape Takayasu Arteritis Treatment & Management - https://emedicine.medscape.com/article/332378-treatment"
        },
        "market_size_estimate": "$98M",
        "market_size_usd": 98490000.0,
        "growth_rate": "5-8% CAGR (high unmet need)"
      },
      "scores": {
        "clinical_signal": 6.0,
        "evidence_quality": 7.0,
        "market_opportunity": 7.3,
        "overall_priority": 6.6,
        "clinical_breakdown": {
          "response_rate": 8.0,
          "safety_profile": 4.0
        },
        "response_rate_score": 8.0,
        "safety_profile_score": 4.0,
        "evidence_breakdown": {
          "sample_size": 6.0,
          "publication_venue": 10.0,
          "followup_duration": 5.0
        },
        "sample_size_score": 6.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 5.0,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 5.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 5.0,
        "unmet_need_score": 10.0
      },
      "rank": 15
    },
    {
      "extraction": {
        "source": {
          "pmid": "36947281",
          "doi": "10.1007/s10067-023-06579-8",
          "url": "https://www.semanticscholar.org/paper/9ed354ac0cf9ef934cf8e0d73077623f24991e7a",
          "title": "A case of hemophagocytic lymphohistiocytosis with a significant response to baricitinib: a first report with review of literature",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Hemophagocytic lymphohistiocytosis",
        "disease_normalized": "Hemophagocytic Lymphohistiocytosis",
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": null,
          "disease_severity": null,
          "comorbidities": null,
          "description": "Patient with hemophagocytic lymphohistiocytosis"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "Significant response observed",
          "primary_endpoint": "Clinical response to HLH treatment",
          "endpoint_result": "Significant response",
          "durability_signal": null,
          "efficacy_summary": "Single patient with HLH showed significant response to baricitinib treatment. This represents the first reported case of baricitinib use in HLH."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No safety information provided in the available case report details.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "First reported case of baricitinib showing significant efficacy in treating hemophagocytic lymphohistiocytosis, supporting the rationale for JAK inhibition in this hyperinflammatory condition.",
        "extraction_timestamp": "2025-12-05T19:22:37.067114",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "Hemophagocytic Lymphohistiocytosis",
        "epidemiology": {
          "us_prevalence_estimate": "1 in 50,000 births",
          "us_incidence_estimate": "1.2 cases per million persons per year",
          "global_prevalence": null,
          "patient_population_size": 6700,
          "prevalence_source": "Swedish national registry study",
          "prevalence_source_url": null,
          "trend": "increasing"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Gamifant (emapalumab-lzsg)",
              "drug_class": "Anti-IFN-gamma monoclonal antibody",
              "efficacy_range": "63%",
              "efficacy_pct": null,
              "annual_cost_usd": 850000.0,
              "line_of_therapy": null,
              "notes": "FDA approved for primary HLH with refractory, recurrent or progressive disease; also approved for HLH/MAS in Still's disease"
            },
            {
              "drug_name": "Dexamethasone",
              "drug_class": "Corticosteroid",
              "efficacy_range": "40-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 2000.0,
              "line_of_therapy": null,
              "notes": "Standard background therapy, off-label use"
            },
            {
              "drug_name": "Cyclosporine A",
              "drug_class": "Calcineurin inhibitor",
              "efficacy_range": "30-50%",
              "efficacy_pct": null,
              "annual_cost_usd": 15000.0,
              "line_of_therapy": null,
              "notes": "Standard combination therapy, off-label use"
            },
            {
              "drug_name": "Etoposide",
              "drug_class": "Chemotherapy",
              "efficacy_range": "50-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 25000.0,
              "line_of_therapy": null,
              "notes": "Conventional HLH-94/HLH-2004 protocol, off-label use"
            }
          ],
          "approved_drug_names": [
            "Gamifant (emapalumab-lzsg)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 0,
          "pipeline_details": null,
          "avg_annual_cost_usd": 223000.0,
          "treatment_paradigm": "Primary treatment involves immunosuppressive chemotherapy protocols (HLH-94/HLH-2004) with etoposide, dexamethasone, and cyclosporine A, followed by hematopoietic stem cell transplant. Emapalumab is used for refractory or progressive cases.",
          "unmet_need": true,
          "unmet_need_description": "High mortality rate despite treatment, limited treatment options for refractory disease, only one FDA-approved drug available, and significant toxicity from conventional chemotherapy protocols",
          "competitive_landscape": "Gamifant (emapalumab) is the only FDA-approved treatment for primary HLH, representing a significant advancement for this rare and often fatal condition. Despite this approval, substantial unmet need remains due to high mortality rates, limited treatment options for refractory cases, and the need for less toxic therapeutic alternatives.",
          "soc_source": "FDA accessdata.fda.gov and eMedicine clinical reference"
        },
        "market_size_estimate": "$1.5B",
        "market_size_usd": 1494100000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)"
      },
      "scores": {
        "clinical_signal": 7.5,
        "evidence_quality": 2.7,
        "market_opportunity": 8.3,
        "overall_priority": 6.5,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 5.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 5.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "followup_duration": 5.0
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 5.0,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 16
    },
    {
      "extraction": {
        "source": {
          "pmid": "33001140",
          "doi": "10.1001/jamadermatol.2020.3260",
          "url": "https://pubmed.ncbi.nlm.nih.gov/33001140/",
          "title": "Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "moderate to severe atopic dermatitis",
        "disease_normalized": "Atopic Dermatitis",
        "is_off_label": true,
        "evidence_level": "Retrospective Study",
        "patient_population": {
          "n_patients": 329,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "topical corticosteroids",
            "topical therapies"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Adults (mean age 33.8 years, 66% male) with moderate to severe atopic dermatitis with inadequate response to topical therapies"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "2 mg or 4 mg once daily",
          "frequency": null,
          "duration": "16 weeks",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "34/111 (31%) for 4mg, 26/109 (24%) for 2mg",
          "responders_n": 60,
          "responders_pct": 27.3,
          "time_to_response": "16 weeks",
          "duration_of_response": null,
          "effect_size_description": "Significant improvement over placebo with both doses, 4mg showing numerically better response",
          "primary_endpoint": "proportion of patients achieving vIGA-AD score of 0 (clear) or 1 (almost clear) with \u22652-point improvement at week 16",
          "endpoint_result": "31% with 4mg baricitinib + TCS, 24% with 2mg baricitinib + TCS vs 15% placebo + TCS",
          "durability_signal": null,
          "efficacy_summary": "Both 2mg and 4mg baricitinib combined with topical corticosteroids showed superior efficacy compared to placebo plus topical corticosteroids in achieving clear or almost clear skin. The 4mg dose showed numerically better response rates across multiple efficacy endpoints including EASI75/90 and itch reduction."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": 20,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "The study reported an acceptable safety profile for baricitinib in combination with topical corticosteroids. Overall completion rate was high at 94% with 20 total discontinuations across all groups.",
          "safety_profile": "Acceptable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "16 weeks",
        "key_findings": "Baricitinib combined with topical corticosteroids demonstrated superior efficacy to placebo plus topical corticosteroids in moderate to severe atopic dermatitis with acceptable safety profile.",
        "extraction_timestamp": "2025-12-05T19:18:54.233314",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "Atopic Dermatitis",
        "epidemiology": {
          "us_prevalence_estimate": "7.3% of adults",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 16500000,
          "prevalence_source": "Atopic Dermatitis in America Study",
          "prevalence_source_url": "https://pubmed.ncbi.nlm.nih.gov/30389491/",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Dupixent (dupilumab)",
              "drug_class": "IL-4/IL-13 inhibitor biologic",
              "efficacy_range": "60-75%",
              "efficacy_pct": null,
              "annual_cost_usd": 45000.0,
              "line_of_therapy": null,
              "notes": "FDA-approved for moderate-to-severe atopic dermatitis in patients 6 months and older"
            },
            {
              "drug_name": "Adbry (tralokinumab-ldrm)",
              "drug_class": "IL-13 inhibitor biologic",
              "efficacy_range": "50-65%",
              "efficacy_pct": null,
              "annual_cost_usd": 50000.0,
              "line_of_therapy": null,
              "notes": "FDA-approved for moderate-to-severe atopic dermatitis in patients 12 years and older"
            },
            {
              "drug_name": "Opzelura (ruxolitinib cream)",
              "drug_class": "Topical JAK inhibitor",
              "efficacy_range": "40-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 15000.0,
              "line_of_therapy": null,
              "notes": "FDA-approved topical JAK inhibitor for mild-to-moderate atopic dermatitis in patients 2 years and older"
            },
            {
              "drug_name": "Protopic (tacrolimus)",
              "drug_class": "Topical calcineurin inhibitor",
              "efficacy_range": "50-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 3000.0,
              "line_of_therapy": null,
              "notes": "FDA-approved topical treatment for atopic dermatitis"
            },
            {
              "drug_name": "Elidel (pimecrolimus)",
              "drug_class": "Topical calcineurin inhibitor",
              "efficacy_range": "45-65%",
              "efficacy_pct": null,
              "annual_cost_usd": 2500.0,
              "line_of_therapy": null,
              "notes": "FDA-approved topical treatment for atopic dermatitis"
            },
            {
              "drug_name": "Topical corticosteroids",
              "drug_class": "Topical corticosteroid",
              "efficacy_range": "60-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 1500.0,
              "line_of_therapy": null,
              "notes": "Multiple FDA-approved topical corticosteroids for atopic dermatitis"
            },
            {
              "drug_name": "Ebglyss",
              "drug_class": "Biologic",
              "efficacy_range": "50-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 50000.0,
              "line_of_therapy": null,
              "notes": "Recently FDA-approved for atopic dermatitis"
            },
            {
              "drug_name": "Nemluvio",
              "drug_class": "Biologic",
              "efficacy_range": "45-65%",
              "efficacy_pct": null,
              "annual_cost_usd": 45000.0,
              "line_of_therapy": null,
              "notes": "Recently FDA-approved for atopic dermatitis"
            },
            {
              "drug_name": "Zoryve",
              "drug_class": "Topical therapy",
              "efficacy_range": "40-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 8000.0,
              "line_of_therapy": null,
              "notes": "Recently FDA-approved for atopic dermatitis"
            }
          ],
          "approved_drug_names": [
            "Dupixent (dupilumab)",
            "Adbry (tralokinumab-ldrm)",
            "Opzelura (ruxolitinib cream)",
            "Protopic (tacrolimus)",
            "Elidel (pimecrolimus)",
            "Topical corticosteroids",
            "Ebglyss",
            "Nemluvio",
            "Zoryve"
          ],
          "num_approved_drugs": 9,
          "num_pipeline_therapies": 3,
          "pipeline_details": "BSI-045B (Biosion) in Phase II trials for atopic dermatitis, with additional JAK inhibitors and biologics in development",
          "avg_annual_cost_usd": 24500.0,
          "treatment_paradigm": "Step-up approach starting with topical corticosteroids and calcineurin inhibitors for mild-to-moderate disease, progressing to topical JAK inhibitors, then systemic biologics (dupilumab, tralokinumab) for moderate-to-severe disease not controlled with topical therapies",
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": "Atopic dermatitis has multiple FDA-approved treatment options including topical therapies (corticosteroids, calcineurin inhibitors, JAK inhibitors) and systemic biologics (dupilumab, tralokinumab) with good efficacy rates. While treatment options have expanded significantly, some patients still require better long-term management solutions and treatments with fewer side effects.",
          "soc_source": "FDA NDA/BLA Multi-Disciplinary Review and Evaluation - https://www.fda.gov/media/189437/download"
        },
        "market_size_estimate": "$404.2B",
        "market_size_usd": 404250000000.0,
        "growth_rate": "3-5% CAGR (estimated)"
      },
      "scores": {
        "clinical_signal": 5.5,
        "evidence_quality": 7.7,
        "market_opportunity": 7.0,
        "overall_priority": 6.4,
        "clinical_breakdown": {
          "response_rate": 4.0,
          "safety_profile": 7.0
        },
        "response_rate_score": 4.0,
        "safety_profile_score": 7.0,
        "evidence_breakdown": {
          "sample_size": 10.0,
          "publication_venue": 10.0,
          "followup_duration": 3.0
        },
        "sample_size_score": 10.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 3.0,
        "market_breakdown": {
          "competitors": 3.0,
          "market_size": 10.0,
          "unmet_need": 8.0
        },
        "competitors_score": 3.0,
        "market_size_score": 10.0,
        "unmet_need_score": 8.0
      },
      "rank": 17
    },
    {
      "extraction": {
        "source": {
          "pmid": "37877023",
          "doi": "10.3389/fmed.2023.1253795",
          "url": "https://www.semanticscholar.org/paper/03bf722fb89644135cad9b4bd84f3c9c461b5758",
          "title": "Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib",
          "authors": "LC, YW, MZ, JZ, XT, ML",
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Alopecia Universalis (pediatric)",
        "disease_normalized": "Alopecia Areata",
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "topical corticosteroids (mometasone furoate, halometasone)",
            "baricitinib"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "4-year-old male with alopecia universalis for 3 years and allergic rhinitis, no other atopic diseases"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "2 mg once daily",
          "frequency": null,
          "duration": "6 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "0/1 (0%)",
          "responders_n": 0,
          "responders_pct": 0.0,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "No response - SALT score remained 0 throughout treatment",
          "primary_endpoint": "SALT score improvement",
          "endpoint_result": "No improvement in SALT score (remained 0) after 6 months",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib showed no efficacy in this 4-year-old patient with alopecia universalis after 6 months of treatment. The patient subsequently responded well to dupilumab therapy."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": 1,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "lack of efficacy"
          ],
          "safety_summary": "No adverse events reported during baricitinib treatment. Patient was switched to dupilumab due to lack of efficacy.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Fail",
        "efficacy_signal": "None",
        "comparator_baseline": null,
        "follow_up_duration": "6 months",
        "key_findings": "Baricitinib was ineffective for pediatric alopecia universalis in this case, suggesting some patients may be resistant to JAK inhibitor therapy.",
        "extraction_timestamp": "2025-12-05T19:24:26.767636",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "Alopecia Areata",
        "epidemiology": {
          "us_prevalence_estimate": "6.7 million people in the United States",
          "us_incidence_estimate": "20.9 per 100,000 person-years",
          "global_prevalence": null,
          "patient_population_size": 6700000,
          "prevalence_source": "Clinical, Cosmetic and Investigational Dermatology",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4521674/",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Olumiant (baricitinib)",
              "drug_class": "JAK inhibitor",
              "efficacy_range": "30-40%",
              "efficacy_pct": null,
              "annual_cost_usd": 70000.0,
              "line_of_therapy": null,
              "notes": "FDA approved for severe alopecia areata in adults (2022)"
            },
            {
              "drug_name": "Intralesional corticosteroids",
              "drug_class": "Corticosteroid",
              "efficacy_range": "40-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 2000.0,
              "line_of_therapy": null,
              "notes": "FDA approved, limited efficacy in severe disease"
            },
            {
              "drug_name": "Topical corticosteroids",
              "drug_class": "Corticosteroid",
              "efficacy_range": "20-40%",
              "efficacy_pct": null,
              "annual_cost_usd": 1500.0,
              "line_of_therapy": null,
              "notes": "Off-label, first-line for limited disease"
            },
            {
              "drug_name": "Minoxidil",
              "drug_class": "Hair growth stimulant",
              "efficacy_range": "20-30%",
              "efficacy_pct": null,
              "annual_cost_usd": 500.0,
              "line_of_therapy": null,
              "notes": "Off-label use"
            },
            {
              "drug_name": "Calcineurin inhibitors",
              "drug_class": "Immunosuppressant",
              "efficacy_range": "25-35%",
              "efficacy_pct": null,
              "annual_cost_usd": 3000.0,
              "line_of_therapy": null,
              "notes": "Off-label, second-line treatment"
            },
            {
              "drug_name": "Contact immunotherapy (DPCP)",
              "drug_class": "Immunotherapy",
              "efficacy_range": "40-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 2500.0,
              "line_of_therapy": null,
              "notes": "Off-label, topical sensitizer"
            }
          ],
          "approved_drug_names": [
            "Olumiant (baricitinib)",
            "Intralesional corticosteroids"
          ],
          "num_approved_drugs": 2,
          "num_pipeline_therapies": 3,
          "pipeline_details": "Deuruxolitinib (JAK inhibitor) recently FDA approved, other JAK inhibitors in development",
          "avg_annual_cost_usd": 13250.0,
          "treatment_paradigm": "Treatment selection based on disease extent: intralesional corticosteroids for limited disease, systemic JAK inhibitors for severe disease (\u226550% hair loss), with various off-label options as second-line therapy",
          "unmet_need": true,
          "unmet_need_description": "Limited efficacy of available treatments, with only one systemic FDA-approved option for severe disease showing modest response rates, and most treatments used off-label with variable efficacy",
          "competitive_landscape": "Only two FDA-approved treatments exist: baricitinib for severe disease and intralesional corticosteroids for limited disease, both with modest efficacy. Significant unmet need remains with most patients relying on off-label treatments with variable and often disappointing results.",
          "soc_source": "FDA Multidiscipline Review and Medscape Treatment Guidelines, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215830Orig1s000MultidisciplineR.pdf"
        },
        "market_size_estimate": "$88.8B",
        "market_size_usd": 88775000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)"
      },
      "scores": {
        "clinical_signal": 5.5,
        "evidence_quality": 3.3,
        "market_opportunity": 9.0,
        "overall_priority": 5.8,
        "clinical_breakdown": {
          "response_rate": 2.0,
          "safety_profile": 9.0
        },
        "response_rate_score": 2.0,
        "safety_profile_score": 9.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "followup_duration": 7.0
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 7.0,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 18
    },
    {
      "extraction": {
        "source": {
          "pmid": "32669454",
          "doi": "10.1136/rmdopen-2020-001246",
          "url": "https://www.semanticscholar.org/paper/b8c4ffbf3c1761bff7ad4f5fdec37b9d1347d713",
          "title": "Mixed results with baricitinib in biological-resistant adult-onset Still\u2019s disease and undifferentiated systemic autoinflammatory disease",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Adult-onset Still's disease (AOSD) and undifferentiated systemic autoinflammatory disease",
        "disease_normalized": "Adult-onset Still's Disease",
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 3,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "prednisolone",
            "methotrexate",
            "ciclosporin",
            "anakinra",
            "tocilizumab",
            "sarilumab",
            "rituximab",
            "infliximab"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Adults with refractory AOSD (2 patients meeting Yamaguchi criteria) and 1 patient with AOSD-like condition in context of myelodysplastic syndrome, all biological-resistant"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg daily",
          "frequency": null,
          "duration": "8\u00b12 weeks follow-up reported, with one patient followed for 15 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "2/3 (67%)",
          "responders_n": 2,
          "responders_pct": 67.0,
          "time_to_response": "8\u00b12 weeks",
          "duration_of_response": "15 months for P1, 9 months for P3",
          "effect_size_description": "Complete clinical and biochemical remission in responders with normalization of CRP and ESR",
          "primary_endpoint": "clinical and biochemical remission",
          "endpoint_result": "complete remission in 2/3 patients (P1 and P3), no response in 1/3 patients (P2)",
          "durability_signal": null,
          "efficacy_summary": "Mixed results with baricitinib showing complete remission in 2 of 3 patients with biological-resistant AOSD. One patient achieved sustained remission on monotherapy for 15 months, while another patient showed no improvement despite 9 months of treatment."
        },
        "safety": {
          "adverse_events": [
            "Pneumocystis jirovecii pneumonia"
          ],
          "serious_adverse_events": [
            "Pneumocystis jirovecii pneumonia"
          ],
          "sae_count": 1,
          "sae_percentage": 33.0,
          "discontinuations_n": 1,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "lack of efficacy"
          ],
          "safety_summary": "One serious opportunistic infection (Pneumocystis jirovecii pneumonia) occurred in a patient with underlying myelodysplastic syndrome. This represents the first reported case of PCP infection following baricitinib use.",
          "safety_profile": "Concerning"
        },
        "outcome_result": "Mixed",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": "8\u00b12 weeks to 15 months",
        "key_findings": "Baricitinib showed promise in biological-resistant AOSD with 2/3 patients achieving complete remission, but was associated with serious opportunistic infection in one patient.",
        "extraction_timestamp": "2025-12-05T19:24:44.868842",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "Adult-onset Still's Disease",
        "epidemiology": {
          "us_prevalence_estimate": "1-9/100,000 population",
          "us_incidence_estimate": "0.16-0.4 per 100,000 adults",
          "global_prevalence": null,
          "patient_population_size": 16750,
          "prevalence_source": "Orphanet",
          "prevalence_source_url": null,
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Ilaris (canakinumab)",
              "drug_class": "IL-1 inhibitor",
              "efficacy_range": "70-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 150000.0,
              "line_of_therapy": null,
              "notes": "FDA-approved for Adult-Onset Still's Disease and SJIA (2020)"
            },
            {
              "drug_name": "Kineret (anakinra)",
              "drug_class": "IL-1 receptor antagonist",
              "efficacy_range": "65-75%",
              "efficacy_pct": null,
              "annual_cost_usd": 50000.0,
              "line_of_therapy": null,
              "notes": "Orphan designation but not FDA approved for Still's disease; widely used off-label"
            },
            {
              "drug_name": "Actemra (tocilizumab)",
              "drug_class": "IL-6 inhibitor",
              "efficacy_range": "60-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 60000.0,
              "line_of_therapy": null,
              "notes": "Off-label use; FDA-approved for related conditions including SJIA"
            },
            {
              "drug_name": "Gamifant (emapalumab)",
              "drug_class": "IFN-gamma inhibitor",
              "efficacy_range": "50-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 200000.0,
              "line_of_therapy": null,
              "notes": "FDA-approved for MAS in Still's disease (2025)"
            },
            {
              "drug_name": "Corticosteroids",
              "drug_class": "Corticosteroid",
              "efficacy_range": "40-50%",
              "efficacy_pct": null,
              "annual_cost_usd": 2000.0,
              "line_of_therapy": null,
              "notes": "Standard first-line therapy but limited long-term efficacy"
            },
            {
              "drug_name": "Methotrexate",
              "drug_class": "DMARD",
              "efficacy_range": "30-40%",
              "efficacy_pct": null,
              "annual_cost_usd": 5000.0,
              "line_of_therapy": null,
              "notes": "Off-label use as conventional DMARD"
            }
          ],
          "approved_drug_names": [
            "Ilaris (canakinumab)",
            "Gamifant (emapalumab)"
          ],
          "num_approved_drugs": 2,
          "num_pipeline_therapies": 0,
          "pipeline_details": null,
          "avg_annual_cost_usd": 77833.0,
          "treatment_paradigm": "Corticosteroids for initial management, with biologics (particularly IL-1 inhibitors) increasingly used as first-line therapy due to superior efficacy over conventional DMARDs",
          "unmet_need": true,
          "unmet_need_description": "Limited FDA-approved options, frequent relapses, significant side effects from corticosteroids, and potential for life-threatening complications like MAS",
          "competitive_landscape": "Ilaris is the only FDA-approved biologic specifically for AOSD, with anakinra widely used off-label despite lack of FDA approval. Significant unmet need remains due to limited approved options and risk of serious complications requiring specialized treatments like emapalumab for MAS.",
          "soc_source": "FDA Orphan Drug Designations and Approvals Database - https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm"
        },
        "market_size_estimate": "$1.3B",
        "market_size_usd": 1303702750.0,
        "growth_rate": "5-8% CAGR (high unmet need)"
      },
      "scores": {
        "clinical_signal": 5.0,
        "evidence_quality": 4.7,
        "market_opportunity": 8.3,
        "overall_priority": 5.8,
        "clinical_breakdown": {
          "response_rate": 8.0,
          "safety_profile": 2.0
        },
        "response_rate_score": 8.0,
        "safety_profile_score": 2.0,
        "evidence_breakdown": {
          "sample_size": 2.0,
          "publication_venue": 2.0,
          "followup_duration": 10.0
        },
        "sample_size_score": 2.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 10.0,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 19
    },
    {
      "extraction": {
        "source": {
          "pmid": "37087470",
          "doi": "10.1186/s12969-023-00817-8",
          "url": "https://pubmed.ncbi.nlm.nih.gov/37087470/",
          "title": "Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS).",
          "authors": null,
          "journal": null,
          "year": 2023,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, AGS)",
        "disease_normalized": "Type I Interferonopathies",
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 9,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "disease-modifying antirheumatic drugs",
            "interleukin-1-blocking agents",
            "corticosteroids"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "9 Japanese patients (55.6% female, mean age 26 years): 5 with NNS/CANDLE, 3 with SAVI, 1 with AGS"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "Weight and eGFR-based dosing with dose escalation over 8 weeks",
          "frequency": null,
          "duration": "52 weeks (12-24 week primary period plus maintenance)",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": "Sustained through 52 weeks",
          "effect_size_description": "Modest improvement in daily symptom scores, substantial corticosteroid reduction in some patients",
          "primary_endpoint": "Change in mean daily diary score (DDS) from baseline",
          "endpoint_result": "DDS decreased 0.22 in NNS/CANDLE, 0.21 in SAVI at primary endpoint; 0.18 in NNS/CANDLE, 0.27 in SAVI at maintenance endpoint",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib showed clinical benefit in NNS/CANDLE and SAVI patients with decreased daily symptom scores and reduced corticosteroid requirements. The single AGS patient showed minimal improvement with slight increase in symptom scores."
        },
        "safety": {
          "adverse_events": [
            "BK polyomavirus detection",
            "increased blood creatine phosphokinase",
            "anemia",
            "upper respiratory tract infection"
          ],
          "serious_adverse_events": [
            "intracranial hemorrhage (fatal, unrelated to drug)"
          ],
          "sae_count": 3,
          "sae_percentage": 33.3,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "All patients experienced at least one adverse event. Three patients had serious adverse events, with one drug-related SAE and one fatal intracranial hemorrhage deemed unrelated to study drug.",
          "safety_profile": "Acceptable"
        },
        "outcome_result": "Mixed",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": "52 weeks",
        "key_findings": "Baricitinib demonstrated potential therapeutic benefit for rare autoinflammatory interferonopathies, particularly NNS/CANDLE and SAVI, with acceptable safety profile in this vulnerable population.",
        "extraction_timestamp": "2025-12-05T19:19:46.342726",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "Type I Interferonopathies",
        "epidemiology": {
          "us_prevalence_estimate": null,
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": null,
          "prevalence_source": null,
          "prevalence_source_url": null,
          "trend": "increasing"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Olumiant (baricitinib)",
              "drug_class": "JAK inhibitor",
              "efficacy_range": "60-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 70000.0,
              "line_of_therapy": null,
              "notes": "Compassionate use program for Type-1 interferonopathies"
            },
            {
              "drug_name": "Kineret (anakinra)",
              "drug_class": "IL-1 receptor antagonist",
              "efficacy_range": "40-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 50000.0,
              "line_of_therapy": null,
              "notes": "Off-label use for autoinflammatory conditions"
            },
            {
              "drug_name": "Actemra (tocilizumab)",
              "drug_class": "IL-6 receptor antagonist",
              "efficacy_range": "30-50%",
              "efficacy_pct": null,
              "annual_cost_usd": 60000.0,
              "line_of_therapy": null,
              "notes": "Off-label for inflammatory manifestations"
            },
            {
              "drug_name": "Hydroxychloroquine",
              "drug_class": "Antimalarial/immunomodulator",
              "efficacy_range": "20-40%",
              "efficacy_pct": null,
              "annual_cost_usd": 2000.0,
              "line_of_therapy": null,
              "notes": "Off-label for skin manifestations"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 1,
          "pipeline_details": "Baricitinib (JAK inhibitor) available through expanded access program for rare Type-1 interferonopathies",
          "avg_annual_cost_usd": 45500.0,
          "treatment_paradigm": "Symptomatic management with JAK inhibitors showing promise through compassionate use programs, supportive care for organ-specific manifestations",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved therapies specifically for Type I interferonopathies; treatment relies on off-label use of immunosuppressants and experimental JAK inhibitors through compassionate use programs",
          "competitive_landscape": "No FDA-approved treatments exist for Type I interferonopathies, with management relying on off-label immunosuppressants and JAK inhibitors. Significant unmet need exists for targeted therapies addressing the underlying interferon pathway dysfunction.",
          "soc_source": "FDA EUA Document for Baricitinib - https://www.fda.gov/media/144473/download"
        },
        "market_size_estimate": null,
        "market_size_usd": null,
        "growth_rate": "5-10% CAGR (increasing prevalence)"
      },
      "scores": {
        "clinical_signal": 4.0,
        "evidence_quality": 5.7,
        "market_opportunity": 8.3,
        "overall_priority": 5.5,
        "clinical_breakdown": {
          "response_rate": 6.0,
          "safety_profile": 2.0
        },
        "response_rate_score": 6.0,
        "safety_profile_score": 2.0,
        "evidence_breakdown": {
          "sample_size": 4.0,
          "publication_venue": 10.0,
          "followup_duration": 3.0
        },
        "sample_size_score": 4.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 3.0,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 5.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 5.0,
        "unmet_need_score": 10.0
      },
      "rank": 20
    },
    {
      "extraction": {
        "source": {
          "pmid": "40772496",
          "doi": "10.2340/actadv.v105.43464",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40772496/",
          "title": "Drug Survival and Predictors of Systemic Treatment Outcome in Atopic Dermatitis: Data From a Nationwide Swedish Cohort.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Atopic Dermatitis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Retrospective Study",
        "patient_population": {
          "n_patients": 30,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Swedish patients with atopic dermatitis, median age 28 years, 50% male, median baseline EASI score 10"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": null,
          "frequency": null,
          "duration": "up to 2 years follow-up",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "Poor drug survival compared to other treatments",
          "primary_endpoint": "Drug survival (time to treatment discontinuation)",
          "endpoint_result": "14.2% drug survival at 2 years",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib showed poor drug survival in atopic dermatitis with only 14.2% of patients remaining on treatment at 2 years. This was significantly worse than methotrexate with a hazard ratio of 1.96 for drug discontinuation."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "side effects",
            "lack of efficacy",
            "other causes"
          ],
          "safety_summary": "Safety data not specifically reported for baricitinib alone. Side effects were cited as one of the reasons for treatment discontinuation across all treatments.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Fail",
        "efficacy_signal": "None",
        "comparator_baseline": null,
        "follow_up_duration": "2 years",
        "key_findings": "Baricitinib had the poorest drug survival among JAK inhibitors for atopic dermatitis treatment, with significantly higher discontinuation rates than methotrexate.",
        "extraction_timestamp": "2025-12-05T19:21:27.062689",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "Atopic Dermatitis",
        "epidemiology": {
          "us_prevalence_estimate": "7.3% of adults",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 16500000,
          "prevalence_source": "Atopic Dermatitis in America Study",
          "prevalence_source_url": "https://pubmed.ncbi.nlm.nih.gov/30389491/",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Dupixent (dupilumab)",
              "drug_class": "IL-4/IL-13 inhibitor biologic",
              "efficacy_range": "60-75%",
              "efficacy_pct": null,
              "annual_cost_usd": 45000.0,
              "line_of_therapy": null,
              "notes": "FDA-approved for moderate-to-severe atopic dermatitis in patients 6 months and older"
            },
            {
              "drug_name": "Adbry (tralokinumab-ldrm)",
              "drug_class": "IL-13 inhibitor biologic",
              "efficacy_range": "50-65%",
              "efficacy_pct": null,
              "annual_cost_usd": 50000.0,
              "line_of_therapy": null,
              "notes": "FDA-approved for moderate-to-severe atopic dermatitis in patients 12 years and older"
            },
            {
              "drug_name": "Opzelura (ruxolitinib cream)",
              "drug_class": "Topical JAK inhibitor",
              "efficacy_range": "40-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 15000.0,
              "line_of_therapy": null,
              "notes": "FDA-approved topical JAK inhibitor for mild-to-moderate atopic dermatitis in patients 2 years and older"
            },
            {
              "drug_name": "Protopic (tacrolimus)",
              "drug_class": "Topical calcineurin inhibitor",
              "efficacy_range": "50-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 3000.0,
              "line_of_therapy": null,
              "notes": "FDA-approved topical treatment for atopic dermatitis"
            },
            {
              "drug_name": "Elidel (pimecrolimus)",
              "drug_class": "Topical calcineurin inhibitor",
              "efficacy_range": "45-65%",
              "efficacy_pct": null,
              "annual_cost_usd": 2500.0,
              "line_of_therapy": null,
              "notes": "FDA-approved topical treatment for atopic dermatitis"
            },
            {
              "drug_name": "Topical corticosteroids",
              "drug_class": "Topical corticosteroid",
              "efficacy_range": "60-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 1500.0,
              "line_of_therapy": null,
              "notes": "Multiple FDA-approved topical corticosteroids for atopic dermatitis"
            },
            {
              "drug_name": "Ebglyss",
              "drug_class": "Biologic",
              "efficacy_range": "50-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 50000.0,
              "line_of_therapy": null,
              "notes": "Recently FDA-approved for atopic dermatitis"
            },
            {
              "drug_name": "Nemluvio",
              "drug_class": "Biologic",
              "efficacy_range": "45-65%",
              "efficacy_pct": null,
              "annual_cost_usd": 45000.0,
              "line_of_therapy": null,
              "notes": "Recently FDA-approved for atopic dermatitis"
            },
            {
              "drug_name": "Zoryve",
              "drug_class": "Topical therapy",
              "efficacy_range": "40-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 8000.0,
              "line_of_therapy": null,
              "notes": "Recently FDA-approved for atopic dermatitis"
            }
          ],
          "approved_drug_names": [
            "Dupixent (dupilumab)",
            "Adbry (tralokinumab-ldrm)",
            "Opzelura (ruxolitinib cream)",
            "Protopic (tacrolimus)",
            "Elidel (pimecrolimus)",
            "Topical corticosteroids",
            "Ebglyss",
            "Nemluvio",
            "Zoryve"
          ],
          "num_approved_drugs": 9,
          "num_pipeline_therapies": 3,
          "pipeline_details": "BSI-045B (Biosion) in Phase II trials for atopic dermatitis, with additional JAK inhibitors and biologics in development",
          "avg_annual_cost_usd": 24500.0,
          "treatment_paradigm": "Step-up approach starting with topical corticosteroids and calcineurin inhibitors for mild-to-moderate disease, progressing to topical JAK inhibitors, then systemic biologics (dupilumab, tralokinumab) for moderate-to-severe disease not controlled with topical therapies",
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": "Atopic dermatitis has multiple FDA-approved treatment options including topical therapies (corticosteroids, calcineurin inhibitors, JAK inhibitors) and systemic biologics (dupilumab, tralokinumab) with good efficacy rates. While treatment options have expanded significantly, some patients still require better long-term management solutions and treatments with fewer side effects.",
          "soc_source": "FDA NDA/BLA Multi-Disciplinary Review and Evaluation - https://www.fda.gov/media/189437/download"
        },
        "market_size_estimate": "$404.2B",
        "market_size_usd": 404250000000.0,
        "growth_rate": "3-5% CAGR (estimated)"
      },
      "scores": {
        "clinical_signal": 3.0,
        "evidence_quality": 9.3,
        "market_opportunity": 6.0,
        "overall_priority": 5.3,
        "clinical_breakdown": {
          "response_rate": 1.0,
          "safety_profile": 5.0
        },
        "response_rate_score": 1.0,
        "safety_profile_score": 5.0,
        "evidence_breakdown": {
          "sample_size": 8.0,
          "publication_venue": 10.0,
          "followup_duration": 10.0
        },
        "sample_size_score": 8.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 10.0,
        "market_breakdown": {
          "competitors": 3.0,
          "market_size": 10.0,
          "unmet_need": 5.0
        },
        "competitors_score": 3.0,
        "market_size_score": 10.0,
        "unmet_need_score": 5.0
      },
      "rank": 21
    },
    {
      "extraction": {
        "source": {
          "pmid": "38524384",
          "doi": "10.1177/2050313X241235444",
          "url": "https://www.semanticscholar.org/paper/dbf0762f2d658612639aac768df49760f5d34730",
          "title": "Use of Baricitinib in a patient with treatment-resistant pyoderma gangrenosum",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "pyoderma gangrenosum",
        "disease_normalized": "Pyoderma Gangrenosum",
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "oral corticosteroids",
            "intralesional corticosteroids",
            "minocycline",
            "systemic corticosteroids",
            "colchicine",
            "intravenous immunoglobulin"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "78-year-old female with treatment-resistant pyoderma gangrenosum and metastatic high-grade serous ovarian carcinoma"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg daily",
          "frequency": null,
          "duration": "12 weeks",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "during 12 weeks of treatment",
          "duration_of_response": "axilla and elbow ulcers remained healed at 13 weeks post-discontinuation, lower extremity ulcer recurred 4 weeks after discontinuation",
          "effect_size_description": "complete resolution of 2 ulcers, partial improvement of 1 ulcer",
          "primary_endpoint": "ulcer healing and size reduction",
          "endpoint_result": "right lower extremity ulcer decreased in size, ulcers on right axilla and right elbow resolved completely",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib 4mg daily for 12 weeks led to complete resolution of ulcers on right axilla and elbow, and partial improvement of right lower extremity ulcer. However, the lower extremity ulcer recurred 4 weeks after discontinuation while axilla and elbow ulcers remained healed."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [
            "methicillin-sensitive Staphylococcus aureus right knee septic arthritis"
          ],
          "sae_count": 1,
          "sae_percentage": 100.0,
          "discontinuations_n": 1,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "patient and oncology team decision to resume paclitaxel for cancer treatment"
          ],
          "safety_summary": "Patient developed septic arthritis after discontinuation of baricitinib, though temporal relationship to drug unclear. No other adverse events specifically attributed to baricitinib were reported during treatment period.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Mixed",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": "13 weeks post-discontinuation",
        "key_findings": "Baricitinib showed efficacy in treatment-resistant pyoderma gangrenosum but recurrence occurred after discontinuation in one ulcer.",
        "extraction_timestamp": "2025-12-05T19:22:00.105953",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "Pyoderma Gangrenosum",
        "epidemiology": {
          "us_prevalence_estimate": "5.8 per 100,000 adults",
          "us_incidence_estimate": "0.04 to 5 per 100,000 per year",
          "global_prevalence": null,
          "patient_population_size": 15483,
          "prevalence_source": "PubMed study",
          "prevalence_source_url": "https://pubmed.ncbi.nlm.nih.gov/31400451/",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Prednisone/Prednisolone",
              "drug_class": "Corticosteroid",
              "efficacy_range": "60-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 2000.0,
              "line_of_therapy": null,
              "notes": "First-line systemic therapy, off-label use"
            },
            {
              "drug_name": "Humira (adalimumab)",
              "drug_class": "TNF-alpha inhibitor",
              "efficacy_range": "50-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 80000.0,
              "line_of_therapy": null,
              "notes": "FDA-approved for inflammatory conditions including Crohn's disease and ulcerative colitis"
            },
            {
              "drug_name": "Enbrel (etanercept)",
              "drug_class": "TNF-alpha inhibitor",
              "efficacy_range": "50-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 75000.0,
              "line_of_therapy": null,
              "notes": "FDA-approved for rheumatoid arthritis and psoriasis"
            },
            {
              "drug_name": "Infliximab",
              "drug_class": "TNF-alpha inhibitor",
              "efficacy_range": "50-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 70000.0,
              "line_of_therapy": null,
              "notes": "Off-label use for refractory cases"
            },
            {
              "drug_name": "Cyclosporine",
              "drug_class": "Calcineurin inhibitor",
              "efficacy_range": "50-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 8000.0,
              "line_of_therapy": null,
              "notes": "Second-line immunosuppressant, off-label"
            },
            {
              "drug_name": "Mycophenolate mofetil",
              "drug_class": "Immunosuppressant",
              "efficacy_range": "40-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 5000.0,
              "line_of_therapy": null,
              "notes": "Steroid-sparing agent, off-label"
            },
            {
              "drug_name": "Azathioprine",
              "drug_class": "Immunosuppressant",
              "efficacy_range": "40-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 3000.0,
              "line_of_therapy": null,
              "notes": "Steroid-sparing agent, off-label"
            }
          ],
          "approved_drug_names": [
            "Humira (adalimumab)",
            "Enbrel (etanercept)"
          ],
          "num_approved_drugs": 2,
          "num_pipeline_therapies": 3,
          "pipeline_details": "IL-23 inhibitors (risankizumab, guselkumab), JAK inhibitors, and PDE4 inhibitors are being studied in clinical trials",
          "avg_annual_cost_usd": 35000.0,
          "treatment_paradigm": "No uniformly effective therapy exists. Treatment involves anti-inflammatory agents including corticosteroids as first-line, followed by immunosuppressants and biologic agents. TNF-alpha inhibitors are used for refractory cases.",
          "unmet_need": true,
          "unmet_need_description": "No specific therapy is uniformly effective for pyoderma gangrenosum. Many patients require multiple treatment attempts, and the disease can recur with residual scarring being common.",
          "competitive_landscape": "Limited FDA-approved options exist specifically for pyoderma gangrenosum, with treatment relying primarily on off-label use of immunosuppressants and biologics approved for related inflammatory conditions. Significant unmet need exists due to lack of uniformly effective therapies and high recurrence rates.",
          "soc_source": "Medscape - Pyoderma Gangrenosum Treatment & Management, https://emedicine.medscape.com/article/1123821-treatment"
        },
        "market_size_estimate": "$542M",
        "market_size_usd": 541905000.0,
        "growth_rate": "5-8% CAGR (high unmet need)"
      },
      "scores": {
        "clinical_signal": 5.5,
        "evidence_quality": 2.0,
        "market_opportunity": 8.0,
        "overall_priority": 5.2,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 1.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 1.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "followup_duration": 3.0
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 3.0,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 7.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 7.0,
        "unmet_need_score": 10.0
      },
      "rank": 22
    },
    {
      "extraction": {
        "source": {
          "pmid": "40059465",
          "doi": "10.2340/actadv.v105.41504",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40059465/",
          "title": "Long-term Outcomes of New Systemic Agents in Atopic Dermatitis: Drug Survival Analyses and Treatment Patterns in Daily Practice.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "atopic dermatitis",
        "disease_normalized": "Atopic Dermatitis",
        "is_off_label": true,
        "evidence_level": "Retrospective Study",
        "patient_population": {
          "n_patients": 62,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "cyclosporine A",
            "methotrexate",
            "azathioprine",
            "mycophenolic acid",
            "systemic steroids"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Adult patients with moderate-to-severe atopic dermatitis, median age 42 years, 97.6% had previously received traditional systemic immunosuppressants"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "2-4 mg daily",
          "frequency": null,
          "duration": "median 4 months when discontinued, median 6.5 months when continued",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "Lowest survival rate among all treatments studied",
          "primary_endpoint": "drug survival rate",
          "endpoint_result": "18-month drug survival rate of 20.4%",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib showed the lowest 18-month drug survival rate at 20.4% among all treatments studied. The majority of discontinuations (59.7%) were due to ineffectiveness, indicating poor treatment durability in this population."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": 44,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "ineffectiveness",
            "adverse events",
            "remission",
            "other"
          ],
          "safety_summary": "Of the 44 patients who discontinued baricitinib, 11 (17.7%) discontinued due to adverse events. Dose reduction was successful in only 6.5% of treatment courses, suggesting limited tolerability optimization options.",
          "safety_profile": "Concerning"
        },
        "outcome_result": "Fail",
        "efficacy_signal": "None",
        "comparator_baseline": null,
        "follow_up_duration": "18 months",
        "key_findings": "Baricitinib demonstrated the poorest drug survival among all advanced systemics for atopic dermatitis, with highest discontinuation rate due to ineffectiveness.",
        "extraction_timestamp": "2025-12-05T19:20:00.635311",
        "extraction_confidence": 0.5
      },
      "market_intelligence": {
        "disease": "Atopic Dermatitis",
        "epidemiology": {
          "us_prevalence_estimate": "7.3% of adults",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 16500000,
          "prevalence_source": "Atopic Dermatitis in America Study",
          "prevalence_source_url": "https://pubmed.ncbi.nlm.nih.gov/30389491/",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Dupixent (dupilumab)",
              "drug_class": "IL-4/IL-13 inhibitor biologic",
              "efficacy_range": "60-75%",
              "efficacy_pct": null,
              "annual_cost_usd": 45000.0,
              "line_of_therapy": null,
              "notes": "FDA-approved for moderate-to-severe atopic dermatitis in patients 6 months and older"
            },
            {
              "drug_name": "Adbry (tralokinumab-ldrm)",
              "drug_class": "IL-13 inhibitor biologic",
              "efficacy_range": "50-65%",
              "efficacy_pct": null,
              "annual_cost_usd": 50000.0,
              "line_of_therapy": null,
              "notes": "FDA-approved for moderate-to-severe atopic dermatitis in patients 12 years and older"
            },
            {
              "drug_name": "Opzelura (ruxolitinib cream)",
              "drug_class": "Topical JAK inhibitor",
              "efficacy_range": "40-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 15000.0,
              "line_of_therapy": null,
              "notes": "FDA-approved topical JAK inhibitor for mild-to-moderate atopic dermatitis in patients 2 years and older"
            },
            {
              "drug_name": "Protopic (tacrolimus)",
              "drug_class": "Topical calcineurin inhibitor",
              "efficacy_range": "50-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 3000.0,
              "line_of_therapy": null,
              "notes": "FDA-approved topical treatment for atopic dermatitis"
            },
            {
              "drug_name": "Elidel (pimecrolimus)",
              "drug_class": "Topical calcineurin inhibitor",
              "efficacy_range": "45-65%",
              "efficacy_pct": null,
              "annual_cost_usd": 2500.0,
              "line_of_therapy": null,
              "notes": "FDA-approved topical treatment for atopic dermatitis"
            },
            {
              "drug_name": "Topical corticosteroids",
              "drug_class": "Topical corticosteroid",
              "efficacy_range": "60-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 1500.0,
              "line_of_therapy": null,
              "notes": "Multiple FDA-approved topical corticosteroids for atopic dermatitis"
            },
            {
              "drug_name": "Ebglyss",
              "drug_class": "Biologic",
              "efficacy_range": "50-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 50000.0,
              "line_of_therapy": null,
              "notes": "Recently FDA-approved for atopic dermatitis"
            },
            {
              "drug_name": "Nemluvio",
              "drug_class": "Biologic",
              "efficacy_range": "45-65%",
              "efficacy_pct": null,
              "annual_cost_usd": 45000.0,
              "line_of_therapy": null,
              "notes": "Recently FDA-approved for atopic dermatitis"
            },
            {
              "drug_name": "Zoryve",
              "drug_class": "Topical therapy",
              "efficacy_range": "40-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 8000.0,
              "line_of_therapy": null,
              "notes": "Recently FDA-approved for atopic dermatitis"
            }
          ],
          "approved_drug_names": [
            "Dupixent (dupilumab)",
            "Adbry (tralokinumab-ldrm)",
            "Opzelura (ruxolitinib cream)",
            "Protopic (tacrolimus)",
            "Elidel (pimecrolimus)",
            "Topical corticosteroids",
            "Ebglyss",
            "Nemluvio",
            "Zoryve"
          ],
          "num_approved_drugs": 9,
          "num_pipeline_therapies": 3,
          "pipeline_details": "BSI-045B (Biosion) in Phase II trials for atopic dermatitis, with additional JAK inhibitors and biologics in development",
          "avg_annual_cost_usd": 24500.0,
          "treatment_paradigm": "Step-up approach starting with topical corticosteroids and calcineurin inhibitors for mild-to-moderate disease, progressing to topical JAK inhibitors, then systemic biologics (dupilumab, tralokinumab) for moderate-to-severe disease not controlled with topical therapies",
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": "Atopic dermatitis has multiple FDA-approved treatment options including topical therapies (corticosteroids, calcineurin inhibitors, JAK inhibitors) and systemic biologics (dupilumab, tralokinumab) with good efficacy rates. While treatment options have expanded significantly, some patients still require better long-term management solutions and treatments with fewer side effects.",
          "soc_source": "FDA NDA/BLA Multi-Disciplinary Review and Evaluation - https://www.fda.gov/media/189437/download"
        },
        "market_size_estimate": "$404.2B",
        "market_size_usd": 404250000000.0,
        "growth_rate": "3-5% CAGR (estimated)"
      },
      "scores": {
        "clinical_signal": 2.0,
        "evidence_quality": 10.0,
        "market_opportunity": 6.0,
        "overall_priority": 5.0,
        "clinical_breakdown": {
          "response_rate": 1.0,
          "safety_profile": 3.0
        },
        "response_rate_score": 1.0,
        "safety_profile_score": 3.0,
        "evidence_breakdown": {
          "sample_size": 10.0,
          "publication_venue": 10.0,
          "followup_duration": 10.0
        },
        "sample_size_score": 10.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 10.0,
        "market_breakdown": {
          "competitors": 3.0,
          "market_size": 10.0,
          "unmet_need": 5.0
        },
        "competitors_score": 3.0,
        "market_size_score": 10.0,
        "unmet_need_score": 5.0
      },
      "rank": 23
    }
  ],
  "analysis_date": "2025-12-05T19:35:14.374682",
  "search_queries_used": [],
  "papers_screened": 46,
  "papers_extracted": 25,
  "total_input_tokens": 315771,
  "total_output_tokens": 52355,
  "estimated_cost_usd": 0.0
}